PMC2106561,5.920000000000001e-05,FIGURE 9. High magnification of a reticular inclusion observed in the cytoplasm of an infected cell.)< 110.000.,doi.org/10.1083/jcb.24.1.57,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC2106561_1\10_1.jpg
PMC2106561,5.920000000000001e-05,"FIGURE 13 ML cell sampled 20 hours after inoculation with mouse hepatitis virus. A big cytoplasmicinclusion formed by tubules and cisternae containing virus is observed in the cytoplasm. )< 15,000.",doi.org/10.1083/jcb.24.1.57,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC2106561_1\15_1.jpg
PMC2106561,5.920000000000001e-05,"FIGURE 17. Portion of the cytoplasm of a partially disintegrated, infected M L cell. N u m e r o u s virusparticles are observed inside dilated cisternae. Accumulations of dense granules are seen. X 60,000.",doi.org/10.1083/jcb.24.1.57,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC2106561_1\19_1.jpg
PMC2106561,5.920000000000001e-05,"FIGUaE 1. Portion of the nucleus (iV) and cytoplasm of an M L cell from a non-infectedculture. In the cytoplasm are seen mitochondria (m) dense corpuscles (L) and the Golglapparatus (G). The Golgi apparatus is surrounded by numerous small vesicles. The arrowon the cell surface indicates a VL-partMe of the type habitually seen in these cells.M ~4,000.",doi.org/10.1083/jcb.24.1.57,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC2106561_1\2_1.jpg
PMC2106561,5.920000000000001e-05,"FIGURE 4. Portions of two non-infected ML cells presenting different aspects of the special pinocytotievesicles (V). Some contain an amorphous substance. The vesicle designated by an arrow has its limitingmembrane partially disrupted. X 45,000.",doi.org/10.1083/jcb.24.1.57,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC2106561_1\4_1.jpg
PMC2106561,5.920000000000001e-05,"FIGURE 5. Part of the cytoplasm of an ML cell infected with hepatitis virus, showing different aspectsof the dense bodies containing virus. The appearance of the particles inside the corpuscles is variable.X 45,000.",doi.org/10.1083/jcb.24.1.57,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC2106561_1\5_1.jpg
PMC2106561,5.920000000000001e-05,"FIGURE 6. Large nucleolus of an ML cell from an infected culture, showing numerous dense spots.N 40,000.",doi.org/10.1083/jcb.24.1.57,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC2106561_1\6_1.jpg
PMC4333202,5.08e-05,"Figure 1 Correlations between virus load and immunological parameters in inÃ¯Â¬Â‚uenza H5N1 infection.(aÃ¢Â€Â“g) Correlations between pharyngeal viral RNA load and total peripheral blood lymphocyte numbers (a)and CD3-positive lymphocyte counts (b), and plasma levels of IP-10 (c), MCP-1 (d), IL-8 (e), IL-6 (f) andIL-10 (g). Throat and blood specimens were obtained in parallel on the same day. SpearmanÃ¢Â€Â™s correlationcoefÃ¯Â¬Âcients (r) and P values are given in each graph. No signiÃ¯Â¬Âcant correlations were observed for MIG(r Ã‚Â¼ 0.41, P Ã‚Â¼ 0.10) and IFN-g (r Ã‚Â¼ 0.48, P Ã‚Â¼ 0.062).",doi.org/10.1038/-1m1477,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC4333202_2\3_1.jpg
PMC553849,6.52e-05,"Fig. 1. Nucleotide sequence of the Fl/F2 overlap region. The three reading frames have single letter amino acid codes, and stop codons are marked asasterisks. The amino acid is shown above the second base of the appropriate codon. ORF in Fl and F2 are underlined, the RSV homology region is indicatedby a dashed line, and the methionine at the start of F2 is boxed. The UUUA consensus is boxed, and complementary bases which may participate in stem-loop formation are heavily underlined.",doi.org/10.1002/j.1460-2075.1987.tb02713.x,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC553849_1\2_1.jpg
PMC553849,6.52e-05,"Figure 4A shows the translation products synthesized in thereticulocyte lysate in response to mRNA derived from BglI-,NcoI- or SnaI-digested pFS1 and their reactivity with the variousPB2 antisera. In each case the major product was a 21 kdpolypeptide, but in addition larger products were observed whosesize depended on the template used for transcription. The sizesof these larger products were exactly as predicted if frame-shiftingwere occurring at the F1/F2 junction. The same mRNA were alsotranslated in wheat germ extracts (Figure 4B) and gave essen-tially the same result, except that the ratio of putative frame-shifted to stopped product was considerably reduced. Immuno-precipitation experiments on the reticulocyte lysate translationproducts using the PB2 antisera confirmed the nature of theputative frame-shift products. Antiserum ab 1 reacted not onlywith the 21 kd polypeptide, but also with each of the larger pro-ducts, indicating that these polypeptides have common N-termini.This is consistent with the larger products being F1/F2 fusionproteins. The reactivity of these proteins with the other PB2 anti-sera correlated well with the expected size of the fusion. The27 kd polypeptide (from the BglI transcript) reacted only withab 1, the 50 kd polypeptide (from the NcoI transcript) with abs1-3, and the 95 kd polypeptide (from the SmaI transcript) withall the PB2 antisera. None of the products could be immuno-precipitated with a control antiserum raised against the unrelatedinfluenza PA protein, and only antiserum ab 1 could precipitatethe 21 kd product, as expected from the DNA sequence of pFS1.Immunoprecipitation of the wheat germ translation products with",doi.org/10.1002/j.1460-2075.1987.tb02713.x,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC553849_1\2_2.jpg
PMC553849,6.52e-05,"Figure 4A shows the translation products synthesized in thereticulocyte lysate in response to mRNA derived from BglI-,NcoI- or SnaI-digested pFS1 and their reactivity with the variousPB2 antisera. In each case the major product was a 21 kdpolypeptide, but in addition larger products were observed whosesize depended on the template used for transcription. The sizesof these larger products were exactly as predicted if frame-shiftingwere occurring at the F1/F2 junction. The same mRNA were alsotranslated in wheat germ extracts (Figure 4B) and gave essen-tially the same result, except that the ratio of putative frame-shifted to stopped product was considerably reduced. Immuno-precipitation experiments on the reticulocyte lysate translationproducts using the PB2 antisera confirmed the nature of theputative frame-shift products. Antiserum ab 1 reacted not onlywith the 21 kd polypeptide, but also with each of the larger pro-ducts, indicating that these polypeptides have common N-termini.This is consistent with the larger products being F1/F2 fusionproteins. The reactivity of these proteins with the other PB2 anti-sera correlated well with the expected size of the fusion. The27 kd polypeptide (from the BglI transcript) reacted only withab 1, the 50 kd polypeptide (from the NcoI transcript) with abs1-3, and the 95 kd polypeptide (from the SmaI transcript) withall the PB2 antisera. None of the products could be immuno-precipitated with a control antiserum raised against the unrelatedinfluenza PA protein, and only antiserum ab 1 could precipitatethe 21 kd product, as expected from the DNA sequence of pFS1.Immunoprecipitation of the wheat germ translation products with",doi.org/10.1002/j.1460-2075.1987.tb02713.x,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC553849_1\2_3.jpg
PMC553849,6.52e-05,"Fig. 2. Construction of plasmids pFS1 and pFS2. To generate pFS1, pVB2 + was linearized with Bgll, partially digested with XmnI and a 5090 bp vectorfragment isolated. This was ligated to a 497 bp HincIl-BamHI fragment from PB70, a fragment containing the region of IBV sequence from bp12 012-12 509. For construction of pFS2, pVB2 + was linearized with Bgll, partially digested with HindI and a 5023 bp vector fragment isolated. Thiswas ligated with a complementary pair of oligonucleotides synthesized to include 22 nucleotides corresponding to those from positions 12 368-12 389 of theIBV genome (see Figure 1) and BamH1 and HindU overhanging ends.",doi.org/10.1002/j.1460-2075.1987.tb02713.x,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC553849_1\3_1.jpg
PMC553849,6.52e-05,"Fig. 3. Diagram showing the predicted sizes of protein products and thereactivity of these products with PB2 antisera which would be expected if adetectable ribosomal frame-shifting event were to occur at the F1/F2junction during translation of mRNA derived from BglI-, NcoI- or SnaI-digested pFS1 template.",doi.org/10.1002/j.1460-2075.1987.tb02713.x,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC553849_1\3_2.jpg
PMC553849,6.52e-05,"Fig. 3. Diagram showing the predicted sizes of protein products and thereactivity of these products with PB2 antisera which would be expected if adetectable ribosomal frame-shifting event were to occur at the F1/F2junction during translation of mRNA derived from BglI-, NcoI- or SnaI-digested pFS1 template.",doi.org/10.1002/j.1460-2075.1987.tb02713.x,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC553849_1\3_3.jpg
PMC553849,6.52e-05,"Fig. 4. Panel A. Reticulocyte lysate translation products synthesized in response to RNA transcribed from BglI-, NcoI- or SmnaI-digested pFSl. RNA wasprepared and translated as described in Materials and methods. Products were analysed directly (total) or immunoprecipitated with antiserum as indicatedabove each track. Marker tracks contained 14C-labelled mol. wt markers. Polypeptides were labelled with [35S]methionine, separated on 15%SDS-polyacrylamide gels and detected by autoradiography. Panel B. Wheat germ translation products synthesized in response to in vitro transcripts producedas for panel A. Translations were performed as described in Materials and methods. Samples were analysed directly or immunoprecipitated with antiserum asindicated above each track.",doi.org/10.1002/j.1460-2075.1987.tb02713.x,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC553849_1\4_1.jpg
PMC553849,6.52e-05,Fig. 5. Comparison of nucleotide sequences from the IBV F1/F2 and RSV gag/pol junction. The region of IBV sequence included in plasmid pFS2 isoverlined.,doi.org/10.1002/j.1460-2075.1987.tb02713.x,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC553849_1\4_2.jpg
PMC553849,6.52e-05,"Fig. 6. Panel A. Diagram showing the predicted sizes of protein productsPB32 and the reactivity of these products withexpected if a detectable ribosomal frame-shifting event were to occur at theSnial- Fl/F2 junction during traslation of mRNA derived from Pvull- ordigested pFS2 template. Panel B. Reticulocyte lysate translation productssynthesized in response to RNA transcribed from Pvull- or SinwI-digestedpFS2. RNA was prepared and translated as described in Materials andmethods. Products were analysed directly (total) or immunoprecipitated withantiserum as indicated above each track. Marker tracks contained14C-labelled mol. wt markers. Polypeptides were labelled with[35S]methionine, separated on 15% SDS-polyacrylamide gels and detectedby autoradiography. Plasmid pFS2 does not contain the coding sequencesfor the region of the influenza virus PB2 protein recognized by ab 2.",doi.org/10.1002/j.1460-2075.1987.tb02713.x,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC553849_1\5_1.jpg
PMC553849,6.52e-05,"Fig. 7. Predicted RNA secondary structures at ribosomal frame-shift sites. The potential signals for frame-shifting are boxed, and the termination codons forthe upstream ORF are indicated by a heavy line. The retrovirus structures shown are taken from Rice et al. (1985) (BLV) and Jacks et al. (1987) (MMTV).The IBV structure was obtained by using the 'fold' program of Jacobson et al. (1984).",doi.org/10.1002/j.1460-2075.1987.tb02713.x,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC553849_1\6_1.jpg
PMC553849,6.52e-05,"Figure 2). The resulting plasmid had PB2 sequence information from position486-798 bases replaced by the oligonucleotide. As with pFSl, pFS2 was designedsuch that ribosomes could translate the length of the PB2 gene if a frame-shiftwere to occur from frame 1 to frame 3 of PB2. The junctions were confirmedby nucleotide sequencing as before.All plasmids were transformed into Fscherichia coli TG1 by standard procedures(Hanahan, 1983).Antisera against defined regions of the influenza virus PB2 proteinAntisera against five defined regions of the PB2 protein were prepared by inser-tion of five overlapping regions of the PB2 gene (covering the entire gene se-quence) at the C-terminus of a I3-galactosidase gene using the pEX series ofbacterial expression plasmids (Stanley and Luzio, 1984). The resulting fusionproteins were purified by elution from polyacryalmide gels and used to immunizerabbits. The sequence information to which each of the five antisera (abs 1-5)were raised was 0-483 bp (ab 1), 418-836 bp (ab 2), 708-1488 bp (ab 3),1227-1785 bp (ab 4) and 1777-2341 bp (ab 5). An antiserum was also raisedagainst a region of the influenza PR8 PA protein in a similar way and was usedas a control serum (c).",doi.org/10.1002/j.1460-2075.1987.tb02713.x,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC553849_1\6_2.jpg
PMC553849,6.52e-05,"Figure 2). The resulting plasmid had PB2 sequence information from position486-798 bases replaced by the oligonucleotide. As with pFSl, pFS2 was designedsuch that ribosomes could translate the length of the PB2 gene if a frame-shiftwere to occur from frame 1 to frame 3 of PB2. The junctions were confirmedby nucleotide sequencing as before.All plasmids were transformed into Fscherichia coli TG1 by standard procedures(Hanahan, 1983).Antisera against defined regions of the influenza virus PB2 proteinAntisera against five defined regions of the PB2 protein were prepared by inser-tion of five overlapping regions of the PB2 gene (covering the entire gene se-quence) at the C-terminus of a I3-galactosidase gene using the pEX series ofbacterial expression plasmids (Stanley and Luzio, 1984). The resulting fusionproteins were purified by elution from polyacryalmide gels and used to immunizerabbits. The sequence information to which each of the five antisera (abs 1-5)were raised was 0-483 bp (ab 1), 418-836 bp (ab 2), 708-1488 bp (ab 3),1227-1785 bp (ab 4) and 1777-2341 bp (ab 5). An antiserum was also raisedagainst a region of the influenza PR8 PA protein in a similar way and was usedas a control serum (c).",doi.org/10.1002/j.1460-2075.1987.tb02713.x,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC553849_1\6_3.jpg
PMC5865125,5.94e-05,"Figure 1. Potential causal links between obesity and impaired cognitive function, school achievement and futuresuccess. Reverse causation may also occur when cognitive function, school achievement and future success canimpact the 'mediating factors', and both in turn may cause worsening of obesity.",doi.org/10.1002/14651858.CD009728.pub4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC5865125_1\14_1.jpg
PMC5865125,5.94e-05,Figure 2. Study flow diagram.,doi.org/10.1002/14651858.CD009728.pub4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC5865125_1\21_1.jpg
PMC5865125,5.94e-05,Figure 3. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentagesacross all included studies.,doi.org/10.1002/14651858.CD009728.pub4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC5865125_1\26_1.jpg
PMC5865125,5.94e-05,Figure 4. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.,doi.org/10.1002/14651858.CD009728.pub4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC5865125_1\27_1.jpg
PMC5865125,5.94e-05,"Figure 5. Forest plot of comparison: 4 Lifestyle intervention versus control, outcome: 4.1 BMI z-score.",doi.org/10.1002/14651858.CD009728.pub4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC5865125_1\35_1.jpg
PMC5865125,5.94e-05,"Figure 6. Forest plot of comparison: 4 Lifestyle intervention versus control, outcome: 4.2 Total body fat (%).",doi.org/10.1002/14651858.CD009728.pub4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC5865125_1\36_1.jpg
PMC5960580,0.000106494,"Figure 1 | Number of EID events per decade. EIDevents (defined as the temporal origin of an EID,represented by the original case or cluster of casesthat represents a disease emerging in the humanpopulationÃ¢Â€Â”see Methods) are plotted withrespect to a, pathogen type, b, transmission type,c, drug resistance and d, transmission mode (seekeys for details).",doi.org/10.1038/-1ture06536,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC5960580_1\2_1.jpg
PMC5960580,0.000106494,"Figure 1 | Number of EID events per decade. EIDevents (defined as the temporal origin of an EID,represented by the original case or cluster of casesthat represents a disease emerging in the humanpopulationÃ¢Â€Â”see Methods) are plotted withrespect to a, pathogen type, b, transmission type,c, drug resistance and d, transmission mode (seekeys for details).",doi.org/10.1038/-1ture06536,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC5960580_1\2_2.jpg
PMC5960580,0.000106494,"Fig. 3), reflecting greater surveillance and infectious disease researcheffort in richer, developed countries of Europe, North America,",doi.org/10.1038/-1ture06536,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC5960580_1\3_1.jpg
PMC5960580,0.000106494,"Fig. 3), reflecting greater surveillance and infectious disease researcheffort in richer, developed countries of Europe, North America,",doi.org/10.1038/-1ture06536,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC5960580_1\3_2.jpg
PMC5960580,0.000106494,"Figure 3 | Global distribution ofrelative risk of an EID event. Mapsare derived for EID events caused bya, zoonotic pathogens from wildlife,b, zoonotic pathogens from non-wildlife, c, drug-resistant pathogensand d, vector-borne pathogens. Therelative risk is calculated fromregression coefficients and variablevalues in Table 1 (omitting thevariable measuring reportingeffort), categorized by standarddeviations from the mean andmapped on a linear scale from green(lower values) to red (highervalues).",doi.org/10.1038/-1ture06536,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC5960580_1\4_1.jpg
PMC7068984,0.000122452,"Fig. 1 Viral and host factors that influence the pathogenesis of SARS-CoV-2. Bats are the reservoir of a wide variety of coronaviruses, includingsevere acute respiratory syndrome coronavirus (SARS-CoV) -like viruses. SARS-CoV-2 may originate from bats or unknown intermediate hosts andcross the species barrier into humans. Virus-host interactions affect viral entry and replication. Upper panel: Viral factor. SARS-CoV-2 is an enveloped positivesingle-stranded RNA (ssRNA) coronavirus. Two-thirds of viral RNA, mainly located in the first open reading frame (ORF 1a/b), encodes 16 non-structure proteins(NSPs). The rest part of the virus genome encodes four essential structural proteins, including spike (S) glycoprotein, small envelope (E) protein, matrix (M)protein, and nucleocapsid (N) protein, and also several accessory proteins. S glycoprotein of SARS-CoV-2 binds to host cell receptors, angiotensin-convertingenzyme 2 (ACE2), that is a critical step for virus entry. The possible molecules facilitated membrane invagination for SARS-CoV-2 endocytosis are still unclear.Other virus proteins may contribute to pathogenesis. Host factors (Lower panel) can also influence susceptibility to infection and disease progression. Theelderly and people with underlying disease are susceptible to SARS-CoV-2 and tend to develop into critical conditions. RBD, receptor-binding domain; HR1,heptad repeats 1; HR2, heptad repeats 2",doi.org/10.1186/s40779-020-00240-0,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7068984_1\3_1.jpg
PMC7084952,6.7e-05,Figure 1. National epidemic trend of the 2019 coronavirus disease (COVID-19) outbreak in China from 7 January to 2 February 2020.,doi.org/10.3390/ijerph17051729,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7084952_1\6_1.jpg
PMC7086509,6.14e-05,Fig. 1. Small demyelinated area in the spinal cord of a mouse 7 days after virus inoculation.,doi.org/10.1007/BF00691421,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7086509_1\3_1.jpg
PMC7086509,6.14e-05,"Fig. 2. Patchy subpial areas of demyelination in the spinal cord of a mouse 10 days after virusinoculation. A multinucleated giant cell is indicated by the arrow. Luxol Fast Blue, X 200",doi.org/10.1007/BF00691421,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7086509_1\3_2.jpg
PMC7086509,6.14e-05,"Fig. 3. A satellite ceil next to a neuron contains numerous virus particles within cytoplasmicvacuoles. Aggregates of granular material as well as numerous microtubules are seen in thecytoplasm of the infected cell. Spinal cord, 6 days after virus inoculation, X 25000",doi.org/10.1007/BF00691421,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7086509_1\4_1.jpg
PMC7086509,6.14e-05,"Fig.4. Oligodendroeyte containing intracytoplasmic virus particles (upper left) associatedwith aggregates of granular, electron dense material, Ã¢Â€Â¢ 15000. The inset magnifies the outlinedportion (lower left) revealing the connection of the oligodendroeyte with a myelin sheath. Notecontinuity of a myelin lamella with the plasma membrane of the oligodendrocyte (arrow ininset). Spinal cord, 6 days after virus inoculation, X 100000",doi.org/10.1007/BF00691421,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7086509_1\5_1.jpg
PMC7086509,6.14e-05,"Fig. 5. Necrotic cell, possibly an oligodendrocyte, within the white matter of the spinal cord ina mouse 6 days after virus inoculation, X 20000",doi.org/10.1007/BF00691421,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7086509_1\6_1.jpg
PMC7086509,6.14e-05,"Fig.6. Myelin stripping macrophage showing cytoplasmic processes that intrude betweenmyelin lamellae (~rrows). Spin~l cord, 7 days after virus inoculation, X 10000",doi.org/10.1007/BF00691421,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7086509_1\7_1.jpg
PMC7086682,5.870000000000001e-05,"Fig. 1. PAGE of IBV. A. phosphate buffer system, B. tHs-glyeine buffer system, 10 percent aerylamide m both systems, identical samples loaded on all four gels. P. stainedfor protein, C. stained for carbohydrate. As the photographic process did not recordthe red bands as e/early as the blue, the positions of the carbohydrate bands seen withthe naked eye have been marked alongside the appropriate gels",doi.org/10.1007/BF01317539,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7086682_1\5_1.jpg
PMC7086682,5.870000000000001e-05,"Fig'. 2. Densitometer tracings of PAGE of IBV (strain Beaudette, heavy form) on10 per cent aerylamide gels (tris-glyeine buffer system), a) gel stained with CoomassieBrilliant Blue for peptides; b) gel stained with periodate and Sehiff's reagent (PAS)for carbohydrate. Gels run for 5 ~/2hours. Only those bands consistently found in everypreparation have been labelled VP or VGP. 0eeasionally VP 70 showed slight stainingwith PAS as seen here, but this was not reprodueible",doi.org/10.1007/BF01317539,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7086682_1\6_1.jpg
PMC7086682,5.870000000000001e-05,"Fig. 3. Densitometer tracings of PAGE of IBV (strain i 120) on i0 per cent aerylamidegels (tris-glyeine buffer system), stained with Coomassie Brilliant Blue. a) light formof virus (I. 16 density) ; b) heavy form (I. 18 density) ; e) bromelain treated (light form ;heavy form gave identical pattern). Gels run for 6 hours",doi.org/10.1007/BF01317539,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7086682_1\7_1.jpg
PMC7086760,7.85e-05,"Fig'. 6. P l a q u e counts obtained after treatment of 9 2 9 - Evirus with various sera, expressed as a percentage ofthe control (rabbit) serum. E q u a l v o l u m e s of virus a n dtest s e r u m were held at r o o m temperatul""e for t w o hoursa n d then inoculated onto n]onolayers of L 1 3 9 cells. Afteradsorption, these were overlaid with the ""Bristol"" overlaymedium containing either 2 % Rabbit or 2 % test serum.Percentages based on counts of between 70 and 300plaques per serum tested.",doi.org/10.1007/BF01249379,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7086760_1\10_1.jpg
PMC7086760,7.85e-05,"Fig. 7.DEAE-Dextran gavea 140~ increase in the ~""mean plaque count .e_ owhen used at 100 ~g/mlin the overlay medium.Above and below this ~-soconcentration there wasno significant increasein the mean plaquenumber when com-pared with culturesoverlaid with mediumcontaining no Dextran.Between 50 and 200 ~zg/ml of DEAE-Dextranproduced clearer and larger plaques than controls, as seen after fixingand staining the monolayers. Neither type of the sodium Dextransulphate tested gave an increased plaque count.The anti-metabolite, 5-bromodeoxyuridine (BUDR) had been found toimprove the appearance of monolayers of L 132 cells and to facilitate theobservation of cytopathic effects of 229-E virus in roller-tube cultures.When BUDR was included in the ""Bristol"" overlay medium at between50 and 200 ~g/ml it gave an increased plaque count (77% increase at100 ~g/ml; see Fig. 7) and furthermore the quality of the monolayer wasmuch improved.The effects of different agar preparations were investigated. Most wereas efficient as the ion agar, but Agar No. 1 (Oxoid) at a final concentrationof 0.3~o gave a significant increase in the plaque number. Agar concentra-tions as low as 0.1~o have been tried, but below concentrations of 0.3%",doi.org/10.1007/BF01249379,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7086760_1\11_1.jpg
PMC7086760,7.85e-05,Fig. 7. The effects of v a r i o u s a d d i t i v e s in the o v e r l a y me-dium on the numbers of plaques produced by 229-E virusin L132 cells. A DEAE-dextran. 9 500S sodium dextransulphate. 9 200S sodium dextran sulphate. O 5-bromo-deoxyuridine. The symbol O indicates a toxic concentrationof additive.,doi.org/10.1007/BF01249379,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7086760_1\11_2.jpg
PMC7086760,7.85e-05,Fig. 7. The effects of v a r i o u s a d d i t i v e s in the o v e r l a y me-dium on the numbers of plaques produced by 229-E virusin L132 cells. A DEAE-dextran. 9 500S sodium dextransulphate. 9 200S sodium dextran sulphate. O 5-bromo-deoxyuridine. The symbol O indicates a toxic concentrationof additive.,doi.org/10.1007/BF01249379,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7086760_1\11_3.jpg
PMC7086760,7.85e-05,"Fig. 8 shows unstained and uninfected L 132 cells after 4 days incubationat 33~ The majority of the cells are very flat and non-refracti]e, makingthem difficult to photograph. When cultures were infected with B814virus in nasal washings a transient cytopathic effect was observed, in-volving a maximum of 50% of the cells after 4 to 5 days of incubation.Infection of cultures with LP virus resulted in a progressive eytopathiceffect. The cells became very refractile and rounded, and by the 10thday had all fallen off the glass. The EVS virus produced less cell damagethan the B814 virus and so was very difficult to detect.",doi.org/10.1007/BF01249379,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7086760_1\13_1.jpg
PMC7086760,7.85e-05,Fig. 8. U n s t a i n e d prel~aration of L132 cells after 4 days i n c u b a t i o n a t 33~ u n d e r E a g l e ' smedium plus 2 % foetal calf serum. (Ã¢Â€Â¢ 160),doi.org/10.1007/BF01249379,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7086760_1\14_1.jpg
PMC7086760,7.85e-05,Fig'. 9. U n s t a i n e d L132 cells inoculated w i t h a nasal w a s h i n g c o n t a i n i n g B 814 virus. Prepara-tion k e p t u n d e r the same conditions as in Fig 8. (x 160),doi.org/10.1007/BF01249379,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7086760_1\14_2.jpg
PMC7086760,7.85e-05,Fig. 10. Unstained L132 cells infected with LP virus which had 5 tissue culture passages.Conditions were the same as in Fig. 8. (x 160),doi.org/10.1007/BF01249379,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7086760_1\14_3.jpg
PMC7086760,7.85e-05,"Fig. 1. U n i n f e c t e d t t D C S cells ( h u m a n e m b r y o lung) f i x e d a n d s t a i n e d ~dth h a e m a t o x y ] i nand eosin after 48 hours of incubation at 33 ~C. (Ã¢Â€Â¢ 360,)",doi.org/10.1007/BF01249379,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7086760_1\6_1.jpg
PMC7086760,7.85e-05,Fig. 2. HDCS cells infected with 229-E virus and incubated at 33~ for 48 hours. (Ã¢Â€Â¢,doi.org/10.1007/BF01249379,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7086760_1\6_2.jpg
PMC7086760,7.85e-05,Fig. 3. A high magnification of I-IDCS cells infected with 229-E virus. (Ã¢Â€Â¢ 900.),doi.org/10.1007/BF01249379,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7086760_1\7_1.jpg
PMC7086760,7.85e-05,"Fig. 4. A comparison of the titre of virusin the supcrnatant fluid (e-), measuredas TCD~o for HDCS (WI38 cells) aadthe eytopathie effect produced in cul-tures of L132, ""Bristol"" HeLa, and~u cells infected with 229-E virus.The eytopathie effect (CPE) is measuredas the percentage of cells damagedvisibly in the cultures.",doi.org/10.1007/BF01249379,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7086760_1\8_1.jpg
PMC7086760,7.85e-05,Fig. 5. Plaques produced in a monolayer of L 132cells maintained under the 'Bristol' overlay me-diam. Fixed and stained after 6 days at 33 ~(Actual size.),doi.org/10.1007/BF01249379,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7086760_1\9_1.jpg
PMC7092802,5.7999999999999994e-05,"Figure 2. Symptoms and Maximum Body Temperatures According to Day of Illness and Day of Hospitalization, January 16 to January 30, 2020.",doi.org/10.1056/-1EJMoa2001191,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7092802_3\3_1.jpg
PMC7092802,5.7999999999999994e-05,"Figure 3. Posteroanterior and Lateral Chest Radiographs, January 22, 2020 (Illness Day 7, Hospital Day 3).No acute intrathoracic plain-film abnormality was noted.",doi.org/10.1056/-1EJMoa2001191,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7092802_3\5_1.jpg
PMC7092802,5.7999999999999994e-05,"Figure 5. Anteroposterior and Lateral Chest Radiographs, January 26, 2020 (Illness Day 10, Hospital Day 6).Stable streaky opacities in the lung bases were visible, indicating likely atypical pneumonia; the opacities havesteadily increased in density over time.",doi.org/10.1056/-1EJMoa2001191,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7092802_3\6_1.jpg
PMC7092803,0.000163687,Figure 2. Cytopathic Effects in Human Airway Epithelial Cell Cultures after Inoculation with 2019-nCoV.,doi.org/10.1056/-1EJMoa2001017,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7092803_2\4_1.jpg
PMC7092803,0.000163687,Figure 4. Schematic of 2019-nCoV and Phylogenetic Analysis of 2019-nCoV and Other Betacoronavirus Genomes.Shown are a schematic of 2019-nCoV (Panel A) and full-length phylogenetic analysis of 2019-nCoV and other betacoronavirus genomesin the Orthocoronavirinae subfamily (Panel B).,doi.org/10.1056/-1EJMoa2001017,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7092803_2\6_1.jpg
PMC7092819,0.000179547,Figure S1. Representative chest radiographic manifestations in a non-severe and a severe casewith COVID-19,doi.org/10.1056/-1EJMoa2002032,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7092819_1\8_1.jpg
PMC7092819,0.000179547,Fatigue,doi.org/10.1056/-1EJMoa2002032,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7092819_2\17_1.jpg
PMC7092819,0.000179547,Fatigue,doi.org/10.1056/-1EJMoa2002032,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7092819_2\8_1.jpg
PMC7092819,0.000179547,"Figure 1. Distribution of Patients with Covid-19 across Mainland China.Shown are the official statistics of all documented, laboratory-confirmed cases of coronavirus disease 2019 (Covid-19) throughout China,according to the National Health Commission as of February 4, 2020. The numerator denotes the number of patients who were includedin the study cohort and the denominator denotes the number of laboratory-confirmed cases for each province, autonomous region, orprovincial municipality, as reported by the National Health Commission.",doi.org/10.1056/-1EJMoa2002032,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7092819_3\4_1.jpg
PMC7094943,5.610000000000001e-05,"Fig. 1-3, Extended Data Fig. 3, Extended Data Fig. 5-9 have associated raw data.",doi.org/10.1038/s41586-020-2008-3,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7094943_1\2_1.jpg
PMC7094943,5.610000000000001e-05,"Fig. 1-3, Extended Data Fig. 3, Extended Data Fig. 5-9 have associated raw data.",doi.org/10.1038/s41586-020-2008-3,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7094943_3\19_1.jpg
PMC7094943,5.610000000000001e-05,"Fig. 1 | Genome organization of SARS and SARS-like CoVs. The organization of genes for WHCV, bat SL-CoVZC45 and SARS-CoV Tor2.",doi.org/10.1038/s41586-020-2008-3,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7094943_3\2_1.jpg
PMC7094943,5.610000000000001e-05,"Fig. 2 | Maximum likelihood phylogenetic trees of nucleotide sequences ofthe ORF1a, ORF1b, E and M genes of WHCV and related coronaviruses.a, Phylogenetic trees of ORF1a. b, Phylogenetic trees of ORF1b. c, Phylogenetictrees of E. d, Phylogenetic trees of M. EriCoV, Erinaceus coronavirus. Numbers",doi.org/10.1038/s41586-020-2008-3,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7094943_3\3_1.jpg
PMC7094943,5.610000000000001e-05,"Fig. 3 | Possible recombination events in the S gene of sarbecoviruses.a, The sequence similarity plot reveals two putative recombination breakpoints(black dashed lines), with their locations indicated at the bottom. The plotshows similarity comparisons of the S gene of WHCV (query) compared withthe sequences of SARS-CoV Tor2 and bat SARS-like CoVs WIV1, Rf1 and",doi.org/10.1038/s41586-020-2008-3,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7094943_3\4_1.jpg
PMC7094943,5.610000000000001e-05,"Fig. 9), there was no significant evidence for recombination across the",doi.org/10.1038/s41586-020-2008-3,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7094943_3\4_2.jpg
PMC7094993,6.52e-05,"Figure 1 Global examples of emerging and re-emerging infectious diseases, some of which are discussed in the main text. Red represents newly emerging diseases;blue, re-emerging/resurging diseases; black, a Ã¢Â€Â˜deliberately emergingÃ¢Â€Â™ disease. Adapted, with permission, from ref. 23.",doi.org/10.1038/-1ture02759,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7094993_1\2_1.jpg
PMC7094993,6.52e-05,Figure 2 Leading causes of death worldwide. About 15 million (>25%) of 57 million annual deaths worldwide are the direct result of infectious disease. Figures published by theWorld Health Organization (see http://www.who.int/whr/en and ref. 7).,doi.org/10.1038/-1ture02759,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7094993_1\3_1.jpg
PMC7094993,6.52e-05,"Figure 3 Probable cases of severe acute respiratory syndrome (SARS) with onset of illness from 1 November 2002 to 31 July 2003. Cases are given by country.SARS-related deaths are indicated in parentheses. A total of 8,096 cases (and 774 deaths) are presented. Figures published by the World Health Organization (seehttp://www.who.int/csr/sars/country/en).",doi.org/10.1038/-1ture02759,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7094993_1\5_1.jpg
PMC7094993,6.52e-05,"Figure 4 Documented human infections with avian influenza viruses, 1997Ã¢Â€Â“2004.Sporadic cases of mild human illness associated with avian influenza viruses werereported before 1997. See http://www.who.int/csr/disease/influenza/en and ref. 76.",doi.org/10.1038/-1ture02759,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7094993_1\6_1.jpg
PMC7095016,0.000146866,"Figure 1 A 110 kDa protein associates with the S1 domain of SARS-CoV S protein.a, A fusion protein of the S1 domain (S1Ã¢Â€Â“Ig, shaded area), or of the Ã¯Â¬Ârst 327 residues ofthat domain (S1(327)Ã¢Â€Â“Ig, dotted line) with the Fc domain of human IgG1, or culture",doi.org/10.1038/-1ture02145,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095016_1\2_1.jpg
PMC7095016,0.000146866,"Figure 3 Syncytia formation between S-protein- and ACE2-expressing cells. a, 293T cellstransfected with plasmids encoding the HIV-1 envelope glycoprotein gp160 (top row) or",doi.org/10.1038/-1ture02145,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095016_1\3_1.jpg
PMC7095016,0.000146866,"Figure 4 EfÃ¯Â¬Âcient replication of SARS-CoV in the presence of ACE2. a, Mock- orACE2-transfected 293T cells were infected with SARS-CoV for 1 h, and cell supernatants",doi.org/10.1038/-1ture02145,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095016_1\4_1.jpg
PMC7095137,5.5299999999999996e-05,"FIG. 2. cGMP reverses transducin GTPase acceleration by PDE but not PDEy .Single-turnover GTPase measurements were done as described in the legendto Fig. 1. Subsaturating concentrations of PDE (0.2 fLM) and PDE y (0.4 fLM)which caused the same extent of GTPase acceleration were used. cGMPwas added at a saturating concentration of lOOfLM where indicated. Toprevent cGMP hydrolysis by PDE during the experiment the PDE inhibitorZaprinast (100 fLM; May & Baker) was added to all samples. Zaprinast itselfdid not influence the GTPase reaction (not shown). All the data are takenfrom one of three similar experiments and approximated by single exponentsrevealing GTPase rates of 0.031 S-l for test membranes alone, 0.063 S-lfor the membranes in the presence of both PDE and cGMP and 0.13 S-l forall other conditions.",doi.org/10.1038/357417a0,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095137_1\1_1.jpg
PMC7095137,5.5299999999999996e-05,"FIG. 1 Characterization of anti-receptor monoclonal antibodies. Theneutralization activity of six anti-ST cell antibodies (G43 and T35) wasmeasured in four cell systems permissive to TGEV. The neutralizingtitre is expressed as the last of serial fivefold dilutions protecting themonolayer against the viral cytopathic effect (CPE). Monoclonal antibody51.13 is directed against TGEV spike protein S (ref. 17). ST, PD5 andThy are porcine testis, kidney and thyroid cell lines, FCWF is a feline cellline.METHODS. BALB/ c mice were immunized by intraperitoneal injection of5 x 107 intact ST cells three times at l-month intervals and boosted",doi.org/10.1038/357417a0,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095137_1\2_1.jpg
PMC7095137,5.5299999999999996e-05,"FIG. 2 Polypeptides recognized by anti-receptor monoclonal antibodies. Lane1, 3sS_labelied polypeptides from ST-cell extracts immunoprecipitated byantibody G43. Lanes 2-5, polypeptides from pig intestinal brush-bordermembrane immunoprecipitated by the anti-aminopeptidase N(APN) antibody,4H7 (ref. 4) or by antibody G43. Antibodies were incubated in the presence(+) or absence (-) of solubilized brush-border membrane.METHODS. ST cells were labelled by incubation for 6 h with 100 ILCi ml - 13sS-methionine (Amersham) after a 2-h methionine depletion. Intestinalmicrovillar membranes were prepared as described18. Cells or microvillarmembranes were solubilized in immunoprecipitation buffer17.Immunoprecipitated polypeptides were resolved in 8% SDS-PAGE thenfluorographed (lane 1) or stained with Coomassie blue (lanes 2-5).",doi.org/10.1038/357417a0,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095137_1\2_2.jpg
PMC7095137,5.5299999999999996e-05,"FIG. 3 Demonstration of avirus-receptor binding withpurified components. a,Aminopeptidase N (APN)preincubated with orwithout purified antibodyG43 or a control antibodywas incubated in theabsence (-) or presence ofTGEV or bovine coronavirus(BCV) virions, then cen-trifuged through a glycerolcushion. The presence ofAPN-specific bands in thepellets was revealed bywestern blotting. b, Leftpanel, soluble APN wasincubated on plastic dishescoated with TGEV, BCV or rotavirus virions. Bound APN was revealed byimmunoassay. Right panel, APN was preincubated with serial dilutions ofeither G43 or a control antibody and tested for TGEV binding as above.METHODS. Anchor-free APN was purified by immunoadsorbent Chromatogra-phy from porcine intestine microvillar membranes after Triton X-l00solubilization and trypsin treatments. The purity of APN polypeptides wasconfirmed by SDS-PAGE and Coomassie blue staining. TGEV and BCV virionswere purified as described17. Rotavirus virions were purified on a CsCIgradient. a, APN (0.2 ILg) was mixed with a 50 ILg virion suspension in cell",doi.org/10.1038/357417a0,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095137_1\2_3.jpg
PMC7095137,5.5299999999999996e-05,"FIG. 3 Demonstration of avirus-receptor binding withpurified components. a,Aminopeptidase N (APN)preincubated with orwithout purified antibodyG43 or a control antibodywas incubated in theabsence (-) or presence ofTGEV or bovine coronavirus(BCV) virions, then cen-trifuged through a glycerolcushion. The presence ofAPN-specific bands in thepellets was revealed bywestern blotting. b, Leftpanel, soluble APN wasincubated on plastic dishescoated with TGEV, BCV or rotavirus virions. Bound APN was revealed byimmunoassay. Right panel, APN was preincubated with serial dilutions ofeither G43 or a control antibody and tested for TGEV binding as above.METHODS. Anchor-free APN was purified by immunoadsorbent Chromatogra-phy from porcine intestine microvillar membranes after Triton X-l00solubilization and trypsin treatments. The purity of APN polypeptides wasconfirmed by SDS-PAGE and Coomassie blue staining. TGEV and BCV virionswere purified as described17. Rotavirus virions were purified on a CsCIgradient. a, APN (0.2 ILg) was mixed with a 50 ILg virion suspension in cell",doi.org/10.1038/357417a0,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095137_1\2_4.jpg
PMC7095137,5.5299999999999996e-05,"FIG. 3 Demonstration of avirus-receptor binding withpurified components. a,Aminopeptidase N (APN)preincubated with orwithout purified antibodyG43 or a control antibodywas incubated in theabsence (-) or presence ofTGEV or bovine coronavirus(BCV) virions, then cen-trifuged through a glycerolcushion. The presence ofAPN-specific bands in thepellets was revealed bywestern blotting. b, Leftpanel, soluble APN wasincubated on plastic dishescoated with TGEV, BCV or rotavirus virions. Bound APN was revealed byimmunoassay. Right panel, APN was preincubated with serial dilutions ofeither G43 or a control antibody and tested for TGEV binding as above.METHODS. Anchor-free APN was purified by immunoadsorbent Chromatogra-phy from porcine intestine microvillar membranes after Triton X-l00solubilization and trypsin treatments. The purity of APN polypeptides wasconfirmed by SDS-PAGE and Coomassie blue staining. TGEV and BCV virionswere purified as described17. Rotavirus virions were purified on a CsCIgradient. a, APN (0.2 ILg) was mixed with a 50 ILg virion suspension in cell",doi.org/10.1038/357417a0,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095137_1\2_5.jpg
PMC7095137,5.5299999999999996e-05,Fig. 3 legend. Colorimetric assays were done 16 h after infection at amultiplicity of five plaque-forming unitsH Monolayers were fixed and stainedwith a crystal violet solution. The dye incorporated in cells surviving theviral CPE was measured by optical absorbance after solubilization in aceticacid21. Cells were incubated in the presence of G43 antibody or bestatin(1 mM) from 1 h before infection. Immunoprecipitation of 35S-methionine-labelled intracellular polypeptides was as described for Fig. 2.,doi.org/10.1038/357417a0,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095137_1\3_1.jpg
PMC7095137,5.5299999999999996e-05,Fig. 3 legend. Colorimetric assays were done 16 h after infection at amultiplicity of five plaque-forming unitsH Monolayers were fixed and stainedwith a crystal violet solution. The dye incorporated in cells surviving theviral CPE was measured by optical absorbance after solubilization in aceticacid21. Cells were incubated in the presence of G43 antibody or bestatin(1 mM) from 1 h before infection. Immunoprecipitation of 35S-methionine-labelled intracellular polypeptides was as described for Fig. 2.,doi.org/10.1038/357417a0,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095137_1\3_2.jpg
PMC7095137,5.5299999999999996e-05,Fig. 3 legend. Colorimetric assays were done 16 h after infection at amultiplicity of five plaque-forming unitsH Monolayers were fixed and stainedwith a crystal violet solution. The dye incorporated in cells surviving theviral CPE was measured by optical absorbance after solubilization in aceticacid21. Cells were incubated in the presence of G43 antibody or bestatin(1 mM) from 1 h before infection. Immunoprecipitation of 35S-methionine-labelled intracellular polypeptides was as described for Fig. 2.,doi.org/10.1038/357417a0,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095137_1\3_3.jpg
PMC7095368,7.7e-05,"Figure 1 SARS-associated coronavirus and associated lesionsin macaque lungs. a, Virus particles re-isolated from nasalswabs of infected macaques display typical coronavirusmorphology. b, Diffuse alveolar damage in the lung; alveoliare flooded with highly proteinaceous fluid (arrowhead) thatstains dark pink. c, Several syncytia (arrowheads) are present inthe lumen of a bronchiole and surrounding alveoli. Originalmagnifications: a, Ã‡Â‚200,000; b, Ã‡Â‚150; c, Ã‡Â‚100.",doi.org/10.1038/423240a,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095368_2\1_1.jpg
PMC7095410,7.72e-05,FIG. 2 Competitive binding of the RBS antibody andHCV-299E to hAPN. Native mouse NIH3T3 cells (3T3)or NIH3T3 transformants expressing high levels ofhAPN (hAPN-3T3) were tested. Membrane prepar-ations were used in ELISA assays to measure: a.RBS binding; b. HCV-229E binding; or c. competitivebinding of RBS and HCV-229E. d. Aminopeptidase Nenzymatic activity on the surface of intact cells inthe presence of RBS. the hAPN-specific antibodiesWM15 or MY7. or the mouse myeloma protein UPC10(control).METHODS. Cells were Dounce-homogenized andnuclei were removed by low-speed contrifugation.Ceillysates were pelleted by ultracentrifugation andthe membranes resuspended in 10 mM Tris-EDTAwith 1% aprotinin. Protein concentrations weredetermined by Bradford assay (Bio-Rad). Membranepreparations were serially diluted in carbonatebuffer. pH 9.6. incubated overnight on DynatechImmulon 1 microtitre plates. blocked with TBS-Tween buffer (0.15 M NaC!. 0.05 M Tris-HCI.0.001 M EDTA. 0.05% Tween-20) containing 5%BSA. For detection of antibody binding. 100 ....1of a1:50 dilution of either RBS or normal mouse ascitesin TBS-Tween buffer with 0.1% BSA was added toeach well. and peroxidase-labelled goat anti-mouseimmunoglobulin (Boehringer Mannheim) diluted 1:1.000 was used to detectbound antibody. For detection of HCV-229E binding. membrane-coated plateswere incubated with dilutions of HCV-229E or control medium. followed bygoat anti-HCV-229E. biotinylated rabbit anti-goat immunoglobulin and strep-tavidin-peroxidase (Kirkeguard and Perry). For competitive inhibition ofHCV-229E binding by RBS. dilutions of RBS ascites in medium were incubatedwith membranes on plates before and after the addition of HCV-229E.Incubations were at room temperature for 1 h. Assays were completed byaddition of TMB substrate (Kirkeguard and Perry) and read on a Dynatechlaboratories MR700 ELISA Reader. Background values obtained with mem-brane preparations alone were subtracted to give values for specific binding.,doi.org/10.1038/357420a0,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095410_1\2_1.jpg
PMC7095410,7.72e-05,FIG. 2 Competitive binding of the RBS antibody andHCV-299E to hAPN. Native mouse NIH3T3 cells (3T3)or NIH3T3 transformants expressing high levels ofhAPN (hAPN-3T3) were tested. Membrane prepar-ations were used in ELISA assays to measure: a.RBS binding; b. HCV-229E binding; or c. competitivebinding of RBS and HCV-229E. d. Aminopeptidase Nenzymatic activity on the surface of intact cells inthe presence of RBS. the hAPN-specific antibodiesWM15 or MY7. or the mouse myeloma protein UPC10(control).METHODS. Cells were Dounce-homogenized andnuclei were removed by low-speed contrifugation.Ceillysates were pelleted by ultracentrifugation andthe membranes resuspended in 10 mM Tris-EDTAwith 1% aprotinin. Protein concentrations weredetermined by Bradford assay (Bio-Rad). Membranepreparations were serially diluted in carbonatebuffer. pH 9.6. incubated overnight on DynatechImmulon 1 microtitre plates. blocked with TBS-Tween buffer (0.15 M NaC!. 0.05 M Tris-HCI.0.001 M EDTA. 0.05% Tween-20) containing 5%BSA. For detection of antibody binding. 100 ....1of a1:50 dilution of either RBS or normal mouse ascitesin TBS-Tween buffer with 0.1% BSA was added toeach well. and peroxidase-labelled goat anti-mouseimmunoglobulin (Boehringer Mannheim) diluted 1:1.000 was used to detectbound antibody. For detection of HCV-229E binding. membrane-coated plateswere incubated with dilutions of HCV-229E or control medium. followed bygoat anti-HCV-229E. biotinylated rabbit anti-goat immunoglobulin and strep-tavidin-peroxidase (Kirkeguard and Perry). For competitive inhibition ofHCV-229E binding by RBS. dilutions of RBS ascites in medium were incubatedwith membranes on plates before and after the addition of HCV-229E.Incubations were at room temperature for 1 h. Assays were completed byaddition of TMB substrate (Kirkeguard and Perry) and read on a Dynatechlaboratories MR700 ELISA Reader. Background values obtained with mem-brane preparations alone were subtracted to give values for specific binding.,doi.org/10.1038/357420a0,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095410_1\2_2.jpg
PMC7095410,7.72e-05,FIG. 2 Competitive binding of the RBS antibody andHCV-299E to hAPN. Native mouse NIH3T3 cells (3T3)or NIH3T3 transformants expressing high levels ofhAPN (hAPN-3T3) were tested. Membrane prepar-ations were used in ELISA assays to measure: a.RBS binding; b. HCV-229E binding; or c. competitivebinding of RBS and HCV-229E. d. Aminopeptidase Nenzymatic activity on the surface of intact cells inthe presence of RBS. the hAPN-specific antibodiesWM15 or MY7. or the mouse myeloma protein UPC10(control).METHODS. Cells were Dounce-homogenized andnuclei were removed by low-speed contrifugation.Ceillysates were pelleted by ultracentrifugation andthe membranes resuspended in 10 mM Tris-EDTAwith 1% aprotinin. Protein concentrations weredetermined by Bradford assay (Bio-Rad). Membranepreparations were serially diluted in carbonatebuffer. pH 9.6. incubated overnight on DynatechImmulon 1 microtitre plates. blocked with TBS-Tween buffer (0.15 M NaC!. 0.05 M Tris-HCI.0.001 M EDTA. 0.05% Tween-20) containing 5%BSA. For detection of antibody binding. 100 ....1of a1:50 dilution of either RBS or normal mouse ascitesin TBS-Tween buffer with 0.1% BSA was added toeach well. and peroxidase-labelled goat anti-mouseimmunoglobulin (Boehringer Mannheim) diluted 1:1.000 was used to detectbound antibody. For detection of HCV-229E binding. membrane-coated plateswere incubated with dilutions of HCV-229E or control medium. followed bygoat anti-HCV-229E. biotinylated rabbit anti-goat immunoglobulin and strep-tavidin-peroxidase (Kirkeguard and Perry). For competitive inhibition ofHCV-229E binding by RBS. dilutions of RBS ascites in medium were incubatedwith membranes on plates before and after the addition of HCV-229E.Incubations were at room temperature for 1 h. Assays were completed byaddition of TMB substrate (Kirkeguard and Perry) and read on a Dynatechlaboratories MR700 ELISA Reader. Background values obtained with mem-brane preparations alone were subtracted to give values for specific binding.,doi.org/10.1038/357420a0,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095410_1\2_3.jpg
PMC7095410,7.72e-05,"FIG. 3 Flow cytometric analysis of antibody bindingto NIH3T3 transfectants. B, The hAPN-3T3 cellsincubated with either the RBS antibody (solid line)or the control mouse myeloma protein UPCl0 (dot-ted line). b, The hAPN-3T3 cells incubated witheither the MY7 antibody (solid line) or UPC10 (dot-ted line). c, The hAPNmut-3T3 cells incubated witheither the RBS antibody (solid line) or UPC10 (dot-ted line). d, the hAPNmut-3T3 cells incubated witheither the MY7 antibody (solid line) or lJ'Cl0 (dot-ted line).METHODS. Cells (1 x 106 ) were incubated at 4 Ã‚Â°cfor 30 min in a titred excess of RBS,MY7 (Coulter),or control mouse myeloma protein (UPC10;Organon-Teknika-Cappel). After being washedtwice with cold staining medium (Dulbecco'smodified Eagle's medium, supplemented with 10%fetal bovine serum, L-glutamine, 10 mM I-EPES,antibiotics and 2 mM sodium azide), the cells wereincubated at 4 Ã‚Â°c for 30 min in a titred excess offluoresceinated, affinity-purified goat antiserum tomouse immunoglobulins (Coulter). Washed cellswere resuspended in cold staining medium con-taining 0.25 mM propidium iodide and those thatexcluded the dye were analysed by flow cytometry.",doi.org/10.1038/357420a0,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095410_1\3_1.jpg
PMC7095418,0.000106635,"Fig. 1 | Genome characterization of 2019-nCoV. a, Metagenomics analysis ofnext-generation sequencing of BALF from patient ICU06. b, Genomicorganization of 2019-nCoV WIV04. M, membrane. c, Similarity plot based onthe full-length genome sequence of 2019-nCoV WIV04. Full-length genomesequences of SARS-CoV BJ01, bat SARSr-CoV WIV1, bat coronavirus RaTG13 andZC45 were used as reference sequences. d, Phylogenetic tree based on",doi.org/10.1038/s41586-020-2012-7,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095418_1\2_1.jpg
PMC7095418,0.000106635,"Fig. 2 | Molecular and serological investigation of patient samples.a, Molecular detection of 2019-nCoV in seven patients. Patient information canbe found in Extended Data Tables 1, 2. Detection methods are described inthe Methods. AS, anal swab; OS, oral swab. b, Dynamics of 2019-nCoV antibodylevels in one patient who showed signs of disease on 23 December 2019 (ICU-06). OD ratio, optical density at 450Ã¢Â€Â“630 nm. The right and left y axes indicate",doi.org/10.1038/s41586-020-2012-7,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095418_1\3_1.jpg
PMC7095418,0.000106635,"Fig. 3 | Analysis of the receptor use of 2019-nCoV. Determination of virusinfectivity in HeLa cells that expressed or did not express (untransfected)ACE2. The expression of ACE2 plasmid with S tag was detected using mouseanti-S tag monoclonal antibody. hACE2, human ACE2; bACE2, ACE2 ofRhinolophus sinicus (bat); cACE2, civet ACE2; sACE2, swine ACE2 (pig); mACE2,mouse ACE2. Green, ACE2; red, viral protein (N); blue, DAPI (nuclei). Scale bars,10 ÃŽÂ¼m.",doi.org/10.1038/s41586-020-2012-7,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095418_1\4_1.jpg
PMC7095783,5.629999999999999e-05,"Figure 1 ACE2 is a crucial receptor for SARS-CoV infections in vivo. (a,b) SARS-CoV replication (a) and detection of SARS-CoV Spike RNA (b) in wild-type (WT)and Ace2 knockout mice. Viral replication was determined from lung tissue at day 2 of infection. Virus titers (mean log10TCID50 per gram lung tissue) are shownfor individual mice. n = 15 per group. SARS-CoV Spike RNA expression was assayed using real-time RT-PCR and normalized to mouse Actb. Data are shown asmean + s.e.m. n = 15 per group. **P < 0.01. (c) Lung histopathology (original magnification ÃƒÂ—200) and (d) lung injury scores as defined by leukocyte infiltrationof control and SARS-CoVÃ¢Â€Â“infected wild-type and Ace2 knockout mice. Lung samples were taken on day 6 after SARS-CoV infection.",doi.org/10.1038/-1m1267,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095783_3\2_1.jpg
PMC7095783,5.629999999999999e-05,"Figure 2 Downregulation of ACE2 expression by SARS-CoV infection and SARS-CoV Spike protein. (a) Schematic diagram of the renin-angiotensin systemin acute lung failure and proposed SARS-CoV action. (b) Decreased ACE2 protein, but normal ACE levels, in the lungs of SARS-CoVÃ¢Â€Â“infected mice. Lunghomogenates were prepared from control and SARS-CoVÃ¢Â€Â“infected wild-type or Ace2 knockout (KO) mice on day 2 and analyzed by western blot.(c) Binding of recombinant Spike(S-1190)-Fc protein to human ACE2 (hACE2) and mouse ACE2 (mACE2) in pull-down assays. Spike-Fc but not control-Fc protein pulled down hACE2 and mACE2 from total-cell extracts of A549 human alveolar epithelial cells and IMCD mouse kidney epithelial cells,respectively. Total lysates are shown as controls. (d) Binding of Spike-Fc protein to human and mouse ACE2 in cell culture. 293 cells transfected withhACE2 or mACE2 were incubated with Spike-Fc and the binding was detected by FACS (blue lines). Nontransfected 293 cells incubated with Spike-Fcfollowed by Fc-specific antibodies are shown as controls (black line). (e) Decreased cell-surface expression of ACE2 after binding to Spike-Fc protein at37 Ã‚Â°C compared to 4 Ã‚Â°C in Vero E6 cells. ACE2 surface expression was detected at 3 h of incubation with Spike-Fc using an ACE2-specific monoclonalantibody. Similar data were obtained using Fc-specific antibody to directly detect surface-bound Spike-Fc and to avoid masking of the ACE2 epitope.Representative FACS histograms are shown including a background control with an isotype-matched antibody.",doi.org/10.1038/-1m1267,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095783_3\2_2.jpg
PMC7095783,5.629999999999999e-05,"Figure 3 The SARS-CoV Spike protein enhancesthe severity of acute lung injury. (a) Lung elastancemeasurements after saline or acid instillation inSpike-Fc proteinÃ¢Â€Â“(5.5 nmol/kg) or control-FcÃ¢Â€Â“(5.5 nmol/kg) treated wild-type mice. n = 5Ã¢Â€Â“7per group. *P < 0.05 for the whole time coursecomparing Spike-FcÃ¢Â€Â“treated and control-FcÃ¢Â€Â“treated wild-type mice after acid injury. (b) Lunghistopathology. Representative images are shown.Original magnification, ÃƒÂ—200. (c) Lung injury score(Supplementary Table 1 online). **P < 0.01 versuscontrol-FcÃ¢Â€Â“treated wild-type. (d) Wet to dry weightratios of lungs as readout for pulmonary edema incontrol and Spike-FcÃ¢Â€Â“treated mice in the presenceor absence of acid-induced lung injury.*P < 0.05 between control and Spike-FcÃ¢Â€Â“treatedmice with acid challenge. (e) Severe acute lungfailure by Spike(S318-510)-Fc (5.5 nmol/kg)treatment in acid-challenged mice. The scheme(upper panel) shows the ACE2-binding domain ofSpike (S318-510). Lung elastance measurements(lower panel) showed that Spike(S318-510)-Fc induced severe acute lung failure in acid-challenged wild-type mice, comparable toSpike(S1190)-Fc. n = 5Ã¢Â€Â“7 per group. P < 0.05for the whole time course comparing Spike(S318-510)-Fc or Spike(S1190)-FcÃ¢Â€Â“treated and control-FcÃ¢Â€Â“treated wild-type mice after acid injury. (f) Lungelastance measurements after acid instillation inSpike-Fc proteinÃ¢Â€Â“(S1190; 5.5 nmol/kg) or control-FcÃ¢Â€Â“(5.5 nmol/kg) treated Ace2 knockout (KO)mice. n = 5Ã¢Â€Â“7 for each group.",doi.org/10.1038/-1m1267,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095783_3\3_1.jpg
PMC7095783,5.629999999999999e-05,"Figure 4 SARS-CoV Spike mediates lung injurythrough modulation of the renin-angiotensinsystem. (a,b) Localization of intraperitoneallyinjected Spike(S-1190)-Fc in lung tissue.(a) Spike-Fc was detected by pull-down assaywith Protein G Sepharose and western blot withhuman FcÃ¢Â€Â“specific antibody. Mouse IgG is shownas loading control. (b) Lung immunohistochemistryto detect Spike(S-1190)-Fc or control-Fc proteinusing a human FcÃ¢Â€Â“specific antibody. Spike(S-1190)-Fc localizes to bronchial epithelial cells(left; original magnification, ÃƒÂ—100), inflammatoryexudates cells (middle; original magnification,ÃƒÂ—200), and alveolar pneumocytes (right; originalmagnification, ÃƒÂ—200). (c) Decreased ACE2protein expression in the lungs of Spike(S-1190)-FcÃ¢Â€Â“ treated mice. Lung homogenates were preparedfrom control-FcÃ¢Â€Â“ and Spike(S-1190)-FcÃ¢Â€Â“treatedwild-type mice and analyzed by western blot withACE2-specific antibody. (d) AngII peptide levels inlungs of Spike(S1190)-Fc proteinÃ¢Â€Â“ or controlÃ¢Â€Â“Fc-treated wild-type mice after saline or acidaspiration. AngII levels were determined at3 h by enzyme immunoassay. Bars, mean Ã‚Â± s.e.m.*P < 0.05 comparing Spike(S1190)-FcÃ¢Â€Â“ andcontrol-FcÃ¢Â€Â“treated wild-type mice after acid injury.(e) Lung elastance measurements in acid plusSpike(S1190)-FcÃ¢Â€Â“challenged wild-type micetreated with the AT1R inhibitor losartan (15 mg/kg).n = 4Ã¢Â€Â“6 per group. P < 0.05 comparing losartan-treated Spike(S1190)-FcÃ¢Â€Â“challenged mice withvehicle-treated Spike(S1190)-FcÃ¢Â€Â“challenged mice.(f) Wet to dry weight ratios of lungs of acid andSpike(S1190)-challenged mice in the presence orabsence of losartan (15 mg/kg). n = 4Ã¢Â€Â“6 mice pergroup. *P < 0.05, comparing losartan-treatedwild-type with vehicle-treated wild-type mice at3 h after acid injury.",doi.org/10.1038/-1m1267,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095783_3\4_1.jpg
PMC7095789,6.95e-05,"Figure 1 The VIDISCA method. (a) Schematic overview of steps in VIDISCAmethod. (b) Examples of VIDISCA-mediated virus identification. Specimenswere analyzed using ethidium bromideÃ¢Â€Â“stained agarose (parvovirus B19) orMetaphor agarose (HBV and HIV-1) gel electrophoresis. Lane M, DNAmolecular weight markers; Ã¢Â€Â“, negative controls; +, VIDISCA PCR productsfor HBV (amplified with primers HinP1I-T/MseI-T), parvovirus B19 (HinP1Istandard primer only) or HIV-1 (EcoRI-A/MseI-C primers). (c) VIDISCA PCRproducts for HCoV-NL63. HinP1I-G and MseI-A primers were used forselective amplification; products were visualized by Metaphor agarose gelelectrophoresis. Lanes 1 and 2, duplicate PCR product of cultured HCoV-NL63 harvested from LLC-MK2 cells; 3 and 4, duplicate controlsupernatant from uninfected LLC-MK2 cells; 5 and 6, duplicate negativecontrols containing water; M, 25-bp molecular weight marker. Arrowindicates HCoV-NL63 fragment that was excised from gel and sequenced.",doi.org/10.1038/-1m1024,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095789_3\2_1.jpg
PMC7095789,6.95e-05,Figure 2 Detection of HCoV-NL63 in winter months of 2002 and 2003.(a) Number of patients tested per month. (b) Percentage of patientspositive for HCoV-NL63.,doi.org/10.1038/-1m1024,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095789_3\2_2.jpg
PMC7095789,6.95e-05,Figure 2 Detection of HCoV-NL63 in winter months of 2002 and 2003.(a) Number of patients tested per month. (b) Percentage of patientspositive for HCoV-NL63.,doi.org/10.1038/-1m1024,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095789_3\2_3.jpg
PMC7095789,6.95e-05,"Figure 4 HCoV-NL63 genome organization and phylogenetic analysis.(a) ORFs encoding 1a, 1b, S, ORF3, E, M and N proteins are flanked by286-nucleotide 5Ã¢Â€Â² UTR and 287-nucleotide 3Ã¢Â€Â² UTR. Coordinates of eachORF are provided in Supplementary Table 1 online. (b) Phylogeneticanalysis of HCoV-NL63, using nucleotide sequences predicted to encode1a, 1b, S, M and N proteins (see Supplementary Methods online forGenBank accession numbers). Red, group 1 viruses; blue, group 2;green, group 3; purple, SARS-CoV. MHV, mouse hepatitis virus; IBV, avianinfectious bronchitis virus; BCoV, bovine coronavirus; FCoV, feline entericcoronavirus; CCoV, canine coronavirus; FIPV, feline infectious peritonitisvirus; EqCoV, equine coronavirus; TCoV, turkey coronavirus.",doi.org/10.1038/-1m1024,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095789_3\4_1.jpg
PMC7095806,7.74e-05,"Figure 1 Characterization of the SARS-CoVneutralizing S3.1 monoclonal antibody. (a)Staining of BHK cells transfected with SARS-CoVspike mRNA by purified S3.1 antibody (circles)and by the 6 months convalescent serum(squares). The filled symbols indicate theantibody concentration at which completeneutralization was observed. (b,c) Staining ofSARS-CoV detected by immunoelectronmicroscopy. Top left, negative control; top rightthree panels, convalescent serum; bottom left,supernatant of a non-neutralizing B cell clone;bottom right three panels, S3.1 monoclonalantibody. Bar, 100 nm.",doi.org/10.1038/-1m1080,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095806_3\2_1.jpg
PMC7095806,7.74e-05,"Figure 2 Binding and neutralization capacity of monoclonal antibodiesspecific for SARS-CoV spike. Shown is the staining of BHK cells transfectedwith SARS-CoV spike mRNA by serial dilutions of ten neutralizingmonoclonal antibodies. The symbols indicate the neutralizing titer: that is,the antibody dilution added in the neutralization assay that gave completeviral neutralization.",doi.org/10.1038/-1m1080,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095806_3\4_1.jpg
PMC7095854,0.000105025,"Fig. 1 Electron micrograph of hMPV particles. Virus concentrated from in-fected tMKÃ¢Â€Â“cell culture supernatants were visualized by negative contrastelectron microscopy after PTA staining24. Magnification, ÃƒÂ—92,000.",doi.org/10.1038/89098,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095854_1\2_1.jpg
PMC7095854,0.000105025,"Fig. 2 Schematic representation of genomic fragments obtained fromhMPV. A schematic diagram of APV (3Ã¢Â€Â² to 5Ã¢Â€Â² end, left to right) is shownabove the fragments obtained with RAP-PCR and RT-PCR on virus isolate00-1. Fragments 1Ã¢Â€Â“10 were obtained using RAP-PCR. Fragment A was ob-tained with a primer in RAP-PCR fragments 1 and 2 and a primer designedon basis of alignment of leader and trailer sequences of APV and RSV(ref. 7). Fragment B was obtained with primers designed in RAP-PCR frag-ments 1 and 2 and RAP-PCR fragment 3. Fragment C was obtained withprimers designed in RAP-PCR fragment 3 and RAP-PCR fragments 4Ã¢Â€Â“7.",doi.org/10.1038/89098,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095854_1\2_2.jpg
PMC7095854,0.000105025,"Fig. 4 Phylogenetic analysis of ORFs of hMPV and selected pneu-moviruses. aÃ¢Â€Â“d, The F (panel a), N (panel b), M (panel c), and P (panel d)ORFs of hMPV isolate 00-1 were aligned with those of other members of thegenus Pneumovirinae, and phylogenetic trees were generated by maximumlikelihood analyses using 100 bootstraps and 3 jumbles. The scale repre-senting the number of nucleotide changes is shown for each tree. Bootstrapvalues are based on the consensus trees.",doi.org/10.1038/89098,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095854_1\3_1.jpg
PMC7095854,0.000105025,"Fig. 4 Phylogenetic analysis of ORFs of hMPV and selected pneu-moviruses. aÃ¢Â€Â“d, The F (panel a), N (panel b), M (panel c), and P (panel d)ORFs of hMPV isolate 00-1 were aligned with those of other members of thegenus Pneumovirinae, and phylogenetic trees were generated by maximumlikelihood analyses using 100 bootstraps and 3 jumbles. The scale repre-senting the number of nucleotide changes is shown for each tree. Bootstrapvalues are based on the consensus trees.",doi.org/10.1038/89098,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095854_1\3_2.jpg
PMC7095854,0.000105025,"Fig. 5 Phylogenetic analysis of 9 hMPV isolates. aÃ¢Â€Â“d, Parts of the F (panela), N (panel b), M (panel c) and L (panel d) ORFs of the indicated hMPV iso-lates were amplified by PCR and sequenced directly (fragments of 142, 71,143, and 102 nucleotides, respectively). Phylogenetic trees were generatedas described in Fig. 4. The first 2 numbers in the isolate names refer to theyear from which the isolate originated. We were unable to amplify the Ffragment for isolate 93-4.",doi.org/10.1038/89098,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095854_1\4_1.jpg
PMC7095886,5.3400000000000004e-05,"Figure 1 Proportions of total deaths from major cause-of-death categories, 1909 and 1999, in Chile2. This country illustrates the full transition fromdeveloping to developed status during the twentieth century.",doi.org/10.1038/-1m1150,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095886_1\2_1.jpg
PMC7095886,5.3400000000000004e-05,Figure 2 Changes in life expectancy at birth for both sexes in eightrepresentative countries during the last 55 years5.,doi.org/10.1038/-1m1150,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095886_1\2_2.jpg
PMC7095886,5.3400000000000004e-05,"Figure 3 The changing pattern of farming in South East Asia. Top,traditional mixed homestead; bottom, intensive single-species industry. (Topphoto courtesy of R.A. Weiss)",doi.org/10.1038/-1m1150,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7095886_1\4_1.jpg
PMC7098082,7.390000000000001e-05,Figure 1. PRISMA flow diagram,doi.org/10.1002/14651858.CD011942.pub2,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7098082_1\20_1.jpg
PMC7102538,0.000107867,Figure 1: Study flow diagramSARS-CoV-2=severe acute respiratory syndrome coronavirus 2. FiO2=fraction ofinspired oxygen.,doi.org/10.1016/S2213-2600(20)30079-5,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7102538_1\4_1.jpg
PMC7102538,0.000107867,Figure 2: Survival of critically ill patients with SARS-CoV-2 pneumoniaDashed lines represent 95% CIs. One patient died within 24 h after admission tothe intensive care unit (ICU).,doi.org/10.1016/S2213-2600(20)30079-5,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7102538_1\6_1.jpg
PMC7102549,5.18e-05,Fig. 1. Percentage of patients with PCR-positive nasopharyngeal samples from inclusion to day6 post-inclusion in COVID-19 patients treated with hydroxychloroquine and inCOVID-19 control patients.,doi.org/10.1016/j.ija-1timicag.2020.105949,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7102549_1\5_1.jpg
PMC7102549,5.18e-05,"Fig. 2. Percentage of patients with PCR-positive nasopharyngeal samples from inclusion to day6 post-inclusion in COVID-19 patients treated with hydroxychloroquine only,in COVID-19 patients treated with hydroxychloroquine and azithromycin combination, and in COVID-19 control patients.",doi.org/10.1016/j.ija-1timicag.2020.105949,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7102549_1\6_1.jpg
PMC7102627,8.4e-05,Figure 5. Sera from Convalescent SARS Patients Cross-Neutralize SARS-2-S-Driven EntryPseudotypes harboring the indicated viral surface proteins were incubated with different dilutions of sera from three convalescent SARS patients or sera fromrabbits immunized with the S1 subunit of SARS-S and subsequently inoculated onto Vero cells in order to evaluate cross-neutralization potential. The average ofthree independent experiments performed with triplicate samples is shown. Error bars indicate SEM. Statistical signiÃ¯Â¬Âcance was tested by two-way ANOVA withDunnett posttest.,doi.org/10.1016/j.cell.2020.02.052,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7102627_1\10_1.jpg
PMC7102627,8.4e-05,"Figure S1. Representative Experiment Included in the Average, Related to Figure 1CThe indicated cells lines were inoculated with pseudoparticles harboring the indicated viral glycoprotein or harboring no glycoprotein (no protein) andluciferase activities in cell lysates were determined at 16 h posttransduction. The experiment was performed with quadruplicate samples, the average Ã‚Â± SDis shown.",doi.org/10.1016/j.cell.2020.02.052,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7102627_1\18_1.jpg
PMC7102627,8.4e-05,"Figure S2. Extended Version of the Phylogenetic Tree, Related to Figure 2B",doi.org/10.1016/j.cell.2020.02.052,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7102627_1\19_1.jpg
PMC7102627,8.4e-05,"Figure S3. Protease Requirement for SARS-2-S-Driven Entry and Absence of Unwanted Cytotoxicity of Camostat Mesylate, Related toFigure 4(A and B) Importance of endosomal low pH (A) and activity of CatB/L or TMPRSS2 (B) for host cell entry of SARS-CoV-2 was evaluated by adding inhibitors totarget cells prior to transduction. Ammonium chloride (A) blocks endosomal acidiÃ¯Â¬Âcation while E-64d and camostat mesylate (B) block the activity of CatB/L andTMPRSS2, respectively. Entry into cells not treated with inhibitor was set as 100%.(C) Absence of cytotoxic effects of camostat mesylate. Calu-3 cells were treated with camostat mesylate identically as for infection experiments and cell viabilitywas measured using a commercially available assay (CellTiter-Glo, Promega).",doi.org/10.1016/j.cell.2020.02.052,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7102627_1\20_1.jpg
PMC7102627,8.4e-05,"Figure 1. SARS-2-S and SARS-S Facilitate Entry into a Similar Panel of Mammalian Cell Lines(A) Schematic illustration of SARS-S including functional domains (RBD, receptor binding domain; RBM, receptor binding motif; TD, transmembrane domain) andproteolytic cleavage sites (S1/S2, S20). Amino acid sequences around the two protease recognition sites (red) are indicated for SARS-S and SARS-2-S (asterisksindicate conserved residues). Arrow heads indicate the cleavage site.(B) Analysis of SARS-2-S expression (upper panel) and pseudotype incorporation (lower panel) by western blot using an antibody directed against the C-terminalhemagglutinin (HA) tag added to the viral S proteins analyzed. Shown are representative blots from three experiments. b-Actin (cell lysates) and VSV-M (particles)served as loading controls (M, matrix protein). Black arrow heads indicate bands corresponding to uncleaved S proteins (S0) whereas gray arrow heads indicatebands corresponding to the S2 subunit.(C) Cell lines of human and animal origin were inoculated with pseudotyped VSV harboring VSV-G, SARS-S, or SARS-2-S. At 16 h postinoculation, pseudotypeentry was analyzed by determining luciferase activity in cell lysates. Signals obtained for particles bearing no envelope protein were used for normalization. Theaverage of three independent experiments is shown. Error bars indicate SEM. Unprocessed data from a single experiment are presented in Figure S1.",doi.org/10.1016/j.cell.2020.02.052,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7102627_1\4_1.jpg
PMC7102627,8.4e-05,"Figure 2. SARS-2-S Harbors Amino Acid Residues Critical for ACE2 Binding(A) The S protein of SARS-CoV-2 clusters phylogenetically with S proteins of known bat-associated betacoronaviruses (see Figure S2 for more details).(B) Alignment of the receptor binding motif of SARS-S with corresponding sequences of bat-associated betacoronavirus S proteins, which are able or unable touse ACE2 as cellular receptor, reveals that SARS-CoV-2 possesses crucial amino acid residues for ACE2 binding.",doi.org/10.1016/j.cell.2020.02.052,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7102627_1\6_1.jpg
PMC7102627,8.4e-05,"Figure 3. SARS-2-S Utilizes ACE2 as Cellular Receptor(A) BHK-21 cells transiently expressing ACE2 of human or bat origin, humanAPN, or human DPP4 were inoculated with pseudotyped VSV harboring VSV-G, SARS-S, SARS-2-S, MERS-S, or 229E-S. At 16 h postinoculation, pseu-",doi.org/10.1016/j.cell.2020.02.052,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7102627_1\7_1.jpg
PMC7109868,6.500000000000001e-05,FIGURE 1. Single and dual antibody responses to various coronavirus strains in children(C) or adults (A).,doi.org/10.1093/oxfordjour-1ls.aje.a121171,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7109868_1\3_1.jpg
PMC7109868,6.500000000000001e-05,Figure 1 is a diagram representing thenumber of and per cent antibody responsesto the various coronavirus antigens tested in,doi.org/10.1093/oxfordjour-1ls.aje.a121171,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7109868_1\3_2.jpg
PMC7109868,6.500000000000001e-05,FIGURE 2. Coronavirus isolations and antibody responses in adults with upper respira-tory tract disease.,doi.org/10.1093/oxfordjour-1ls.aje.a121171,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7109868_1\5_1.jpg
PMC7109868,6.500000000000001e-05,FIGURE 3. Coronavirus isolations and antibody responses in children with lower respira-tory tract disease.,doi.org/10.1093/oxfordjour-1ls.aje.a121171,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7109868_1\6_1.jpg
PMC7109910,5.05e-05,"Figure 1. Growth curve of ""IBV-like"" virus (OC38).",doi.org/10.1093/i-1fdis/120.5.576,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7109910_1\3_1.jpg
PMC7110032,0.000102176,"Figures 1-3. Figure 1: two particles found in tissue culture harvests of isolate 489, negatively stained with PTA. The bar inall 3 figures represents 100 mu. X 144,000. Figure 2: 229E virus, negatively stained with PTA. X 144,000. Figure 3: infectiousbronchitis virus, Beaudette 42 strain, negatively staind with PTA. X 144,000.",doi.org/10.1093/i-1fdis/119.3.282,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7110032_1\4_1.jpg
PMC7110200,5.539999999999999e-05,"FIGURE 1. Epidemic curves (numbers of cases by date of symptom onset) for severe acute respiratory syndrome (SARS) outbreaks in a) HongKong, b) Vietnam, c) Singapore, and d) Canada and the corresponding effective reproduction numbers (R) (numbers of secondary infectionsgenerated per case, by date of symptom onset) for e) Hong Kong, f ) Vietnam, g) Singapore, and h) Canada, 2003. Markers (white spaces) showmean values; accompanying vertical lines show 95% confidence intervals. The vertical dashed line indicates the issuance of the first global alertagainst SARS on March 12, 2003; the horizontal solid line indicates the threshold value R = 1, above which an epidemic will spread and belowwhich the epidemic is controlled. Days are counted from January 1, 2003, onwards.",doi.org/10.1093/aje/kwh255,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7110200_1\2_1.jpg
PMC7112372,0.000176007,"Figure 1: Electron microscopy of ultracentrifuged deposit ofcell-culture-grown human pneumonia-associated coronavirusNegatively stained with 3% potassium phospho-tungstate, pH 7Ã‚Â·0.",doi.org/10.1016/S0140-6736(03)13077-2,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112372_1\4_1.jpg
PMC7112372,0.000176007,Figure 2: Thin-section electron micrograph of lung biopsy sample from patient withSARS (A) and of human pneumonia-associated coronavirus infected cells (B),doi.org/10.1016/S0140-6736(03)13077-2,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112372_1\5_1.jpg
PMC7112372,0.000176007,Figure 3: Phylogenetic analysis of the partial protein sequence (215 aminoacids) of the coronavirus (SARS)GenBank accession number AY268070. Tree is constructed by neighbour-jointing method. Horizontal-line distance represents number of sites at which the twosequences compared are different. Bootstrap values deducted from 500 replicates.,doi.org/10.1016/S0140-6736(03)13077-2,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112372_1\6_1.jpg
PMC7112380,6.330000000000001e-05,"Figure 1: Epidemiological description of SARS epidemic in Hong KongA: Temporal pattern of SARS epidemic in Hong Kong by cluster of infection. B: Spatial distribution of population of Hong Kong and district-specific incidence(per 10 000 population) over course of epidemic to date. C: Age distribution of residents of Hong Kong and age-specific incidence (per 10 000 population)over course of epidemic to date. D: Detail of temporal pattern for Amoy Gardens cluster, according to day of admission, and fitted Ã¢ÂÂ¥ distribution.",doi.org/10.1016/S0140-6736(03)13410-1,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112380_1\3_1.jpg
PMC7112380,6.330000000000001e-05,Figure 2: Maximum likelihood estimatesA: Infection-to-onset distribution. B: Time-dependent onset-to-admission distribution as a function of time of onset of clinical symptoms. C: Admission-to-death distribution by patientsÃ¢Â€Â™ age. D: Admission-to-discharge distribution by patientsÃ¢Â€Â™ age. E: Observed and maximum likelihood estimated onset-to-admission intervals in presence of censoring.,doi.org/10.1016/S0140-6736(03)13410-1,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112380_1\5_1.jpg
PMC7112380,6.330000000000001e-05,Figure 3: Non-parametric and maximum-likelihood Ã¢ÂÂ¥probabilities of survival and discharge,doi.org/10.1016/S0140-6736(03)13410-1,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112380_1\6_1.jpg
PMC7112410,0.00011217100000000001,"Figure 1: Temporal clinical profiles in 75 patients with SARSMean (SD) are presented.From 20 patients in whom SARS-associated coronavirusRNA was detected by reverse-transcriptase (RT) PCR inthe initial nasopharyngeal aspirate samples, we collectedfurther nasopharyngeal aspirates, urine, and faecal samplesevery 3 days. In 14 of these patients, quantitative PCR wasdone on the nasopharyngeal aspirates collected on days 5,10, and 15 after onset of symptoms. The nasopharyngeal",doi.org/10.1016/S0140-6736(03)13412-5,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112410_1\3_1.jpg
PMC7112410,0.00011217100000000001,"Figure 2: Chest radiographs and high-resolution CT scans from two SARS patientsA Man aged 34 years admitted for high fever and cough. A: Consolidation seen in left upper and middle zones, which progressed maximally at day 7. B: Atday 20, resolution of consolidation in the left upper and middle zones but new widespread air-space opacities noted; those in left lung base wereconfluent. Man aged 32 years, presented with fever, chills, rigors and myalgia, with clear chest radiograph at admission. C: High-resolution CT of thoraxshows peripheral subpleural consolidation in medial basal segment of left lower lobe. D: Resolution of original left lower-lobe consolidation at day 18. E:Disease complicated by spontaneous pneumomediastinum.",doi.org/10.1016/S0140-6736(03)13412-5,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112410_1\3_2.jpg
PMC7112410,0.00011217100000000001,Figure 3: Kinetics of IgG seroconversion to SARS-associated coronavirus,doi.org/10.1016/S0140-6736(03)13412-5,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112410_1\5_1.jpg
PMC7112410,0.00011217100000000001,Figure 4: Sequential quantitative RT-PCR for SARS-associated coronavirus innasopharyngeal aspirates of 14 SARS patients,doi.org/10.1016/S0140-6736(03)13412-5,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112410_1\6_1.jpg
PMC7112424,6.37e-05,"Figure 2: Immunohistochemical staining for TNF Ã¢ÂÂ£ in lungtissue from patient with H5N1 pneumonia and a patient whodied from non-infective illnessStains made with monoclonal antibody SC-7317 (Santa Cruz Biotechnology,Santa Cruz, CA, USA) at a dilution of 1/10 with antigen retrieval. The33-year-old man with H5N1 pneumonia (left panel) shows greater stainingof alveolar epithelial cells than does the control (right panel).",doi.org/10.1016/S0140-6736(04)15595-5,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112424_1\2_1.jpg
PMC7112424,6.37e-05,"Figure 1: Histological stains of lung tissue from 33-year-oldman with H5N1 pneumoniaLeft panel: intra-alveolar oedema, haemorrhage, and increased fibrin andalveolar macrophages are evident. Haematoxylin and eosin stain used.Right panel: macrophages were shown by use of immunohistochemicalstaining with antibody to CD68.",doi.org/10.1016/S0140-6736(04)15595-5,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112424_1\2_2.jpg
PMC7112434,6.82e-05,"Figure 2: Immunohistochemical identification of cells in lungsfrom cynomolgus macaques infected with SARS-CoVA: Arrows show enlarged type 2 pneumocytes with abundant vesicularcytoplasm and large nucleus containing prominent nucleolus thatfrequently occur along alveolar walls; haematoxylin and eosin. B:Epithelial origin confirmed by positive staining with monoclonal antibodyAE1/AE3, a pan-keratin marker; avidin-biotin complex immunoperoxidasewith diaminobenzidine substrate and hematoxylin counterstain. C: Arrowsshow alveolar macrophages that are common in alveolar lumina;haematoxylin and eosin. D: Macrophage origin is confirmed by positivestaining with monoclonal antibody CD68, a macrophage marker; avidin-biotin complex immunoperoxidase with diaminobenzidine substrate andhaematoxylin counterstain.",doi.org/10.1016/S0140-6736(03)13967-0,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112434_1\5_1.jpg
PMC7112434,6.82e-05,"Figure 1: Histological lesions in lungs from cynomolgusmacaques infected with SARS-CoVA: Early changes of diffuse alveolar damage, characterised by disruptionof alveolar walls and flooding of alveolar lumina with serosanguineousexudate admixed with neutrophils and alveolar macrophages. B: Moreadvanced changes of diffuse alveolar damage, characterised bythickened alveolar walls lined by type 2 pneumocytes, and mainly alveolarmacrophages in alveolar lumina. C: Arrows show hyaline membranes onsurfaces of alveoli. D: A characteristic change is presence of syncytia(arrowhead), here in the lumen of bronchiole. All slides haematoxylin andeosin stained.",doi.org/10.1016/S0140-6736(03)13967-0,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112434_1\5_2.jpg
PMC7112434,6.82e-05,"Figure 3: Immunohistochemical detection of SARS-CoV in lungsfrom experimentally infected cynomolgus macaquesA: Expression of SARS-CoV antigen by two alveolar epithelial cells,probably type 2 pneumocytes. Immunoglobulin G fraction of convalescentserum of SARS patient was used as specific antibody; avidin-biotincomplex immunoperoxidase with diaminobenzidine substrate andhaematoxylin counterstain. B: Expression of SARS-CoV antigen bysyncytium in lumen of alveolar duct. Small cell along the duct wall alsostains positive; avidin-biotin complex immunoperoxidase with 3-amino-9-ethylcarbazole substrate and haematoxylin counterstain.",doi.org/10.1016/S0140-6736(03)13967-0,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112434_1\6_1.jpg
PMC7112434,6.82e-05,"Figure 4: Electron microscopy of SARS-CoV in inoculum,clinical samples, and tissue samples of experimentallyinfected cynomolgus macaquesA: Negative-contrast electron microscopy of virus stock used to inoculatecynomolgus macaques shows the typical club-shaped surface projectionsof coronavirus particles; negatively stained with phosphotungstic acid,bar=100 nm. B: Morphologically identical particles isolated from nasalswabs of infected macaques; negatively stained with phosphotungsticacid, bar=100 nm. C: Transmission electron microscopy of infected Vero118 cell shows viral nucleocapsids with variably electron-dense andelectron-lucent cores in smooth-walled vesicles in the cytoplasm; stainedwith uranyl acetate and lead citrate, bar=500 nm. D: Morphologicallysimilar particles occur in pulmonary lesions of infected macaques, withinvesicles of the Golgi apparatus of pneumocytes; stained with uranylacetate and lead citrate; bar=500 nm.",doi.org/10.1016/S0140-6736(03)13967-0,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112434_1\6_2.jpg
PMC7112492,5.79e-05,Figure 2: SARS showing hyaline-membrane formation andpneumocyte desquamation with focal giant-cell formationHaematoxylin and eosin; ÃÂ«400.,doi.org/10.1016/S0140-6736(03)13413-7,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112492_1\3_1.jpg
PMC7112492,5.79e-05,Figure 1: Open lung biopsy from patient 4Arrow shows an enlarged pneumocyte with amphophilic granularcytoplasm and prominent nucleolus. Haematoxylin and eosin; ÃÂ«400.,doi.org/10.1016/S0140-6736(03)13413-7,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112492_1\3_2.jpg
PMC7112492,5.79e-05,Figure 4: CD68 macrophage antibody staining of giant cells inpatient 5Diaminobenzidine with haematoxylin counterstain; ÃÂ«400.,doi.org/10.1016/S0140-6736(03)13413-7,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112492_1\4_1.jpg
PMC7112492,5.79e-05,Figure 3: SARS-CoV pneumonia with cytomegaly of pneumocytesHaematoxylin and eosin; ÃÂ«400.,doi.org/10.1016/S0140-6736(03)13413-7,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112492_1\4_2.jpg
PMC7112492,5.79e-05,Figure 5: Squamous metaplasia of bronchial mucosa in SARS-CoV pneumoniaHaematoxylin and eosin; ÃÂ«400.,doi.org/10.1016/S0140-6736(03)13413-7,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112492_1\5_1.jpg
PMC7112492,5.79e-05,Figure 6: Septal inflammation of patient 2A: Increased numbers of mononuclear cells with haemophagocytosis.Haematoxylin and eosin; ÃÂ«400. B: The mononuclear cells are CD68positive. Diaminobenzidine with haematoxylin counterstain.,doi.org/10.1016/S0140-6736(03)13413-7,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112492_1\5_2.jpg
PMC7112492,5.79e-05,Figure 7: Thin-section electron micrograph showing a dilatedsecretory vesicle containing a 90 nm coronavirus particleÃÂ«63 000.,doi.org/10.1016/S0140-6736(03)13413-7,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7112492_1\5_3.jpg
PMC7119119,5.41e-05,Fig 1. Example of safe donning and removal of PPE.,doi.org/10.1016/j.ajic.2007.10.007,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7119119_1\35_1.jpg
PMC7121484,0.00010996399999999999,"Figure 1. Onset of Illness among the First 425 Confirmed Cases of Novel Coronavirus (2019-nCoV)Ã¢Â€Â“Infected Pneumonia (NCIP) in Wuhan,China.The decline in incidence after January 8 is likely to be due to delays in diagnosis and laboratory confirmation. China CDC denotes ChineseCenter for Disease Control and Prevention, NHC National Health Commission of the PeopleÃ¢Â€Â™s Republic of China, PCR polymerase chainreaction, WHC Wuhan Health Commission, and WHO World Health Organization.",doi.org/10.1056/-1EJMoa2001316,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7121484_1\4_1.jpg
PMC7121484,0.00010996399999999999,"Figure 2. Key Time-to-Event Distributions.The estimated incubation period distribution (i.e., the time from infection to illness onset) is shown in Panel A. Theestimated serial interval distribution (i.e., the time from illness onset in successive cases in a transmission chain) isshown in Panel B. The estimated distributions of times from illness onset to first medical visit are shown in Panel C.The estimated distributions of times from illness onset to hospital admission are shown in Panel D.",doi.org/10.1056/-1EJMoa2001316,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7121484_1\6_1.jpg
PMC7121484,0.00010996399999999999,"Figure 3. Detailed Information on Exposures and Dates of Illness Onset in Five Clusters Including 16 Cases.Numbers in boxes are calendar dates in December 2019 and January 2020. Data from the 5 secondary cases (patients who had clear ex-posure to only one index case and had no other potential source of infection) were used to estimate the serial interval distribution. Thefirst four clusters were identified in Wuhan, and the fifth cluster was identified in Huanggang.",doi.org/10.1056/-1EJMoa2001316,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7121484_1\7_1.jpg
PMC7127800,6.32e-05,Fig. 1. Daily accumulative cases of laboratory-conÃ¯Â¬Ârmed cases of 2019 coronavirus disease (COVID-19) as of 11 February 2020: (A) daily numbers of global cases; and(B) daily numbers of cases from China [including Hong Kong Special Administrative Region (SAR) and Macau SAR] and outside of China.,doi.org/10.1016/j.ija-1timicag.2020.105924,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7127800_1\4_1.jpg
PMC7127800,6.32e-05,Fig. 2. New daily cases of laboratory-conÃ¯Â¬Ârmed 2019 coronavirus disease (COVID-19) as of 11 February 2020: (A) daily numbers of new cases globally; and (B) daily numbersof new cases from China [including Hong Kong Special Administrative Region (SAR) and Macau SAR] and outside of China.,doi.org/10.1016/j.ija-1timicag.2020.105924,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7127800_1\5_1.jpg
PMC7127800,6.32e-05,Fig. 3. Distribution of laboratory-conÃ¯Â¬Ârmed cases of 2019 coronavirus disease (COVID-19) (A) globally by country and (B) in China by province/region as of 11 February 2020.,doi.org/10.1016/j.ija-1timicag.2020.105924,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7127800_1\6_1.jpg
PMC7130678,7.08e-05,Fig. 3. Daily medication scores of five asthmatic children in relation to respiratory viral in-fection.,doi.org/10.1016/S0022-3476(73)80582-7,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7130678_1\10_1.jpg
PMC7130678,7.08e-05,"Fig. 1. Respiratory symptoms and illness in 12 asthmatic children in relation to respiratoryviral infections (by weeks, 1967 to 1968).",doi.org/10.1016/S0022-3476(73)80582-7,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7130678_1\8_1.jpg
PMC7130678,7.08e-05,"Fig, 2. Respiratory symptoms and illness in 20asthmatic children in relation to respiratory viralinfections (by weeks, 1968 to 1969).",doi.org/10.1016/S0022-3476(73)80582-7,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7130678_1\9_1.jpg
PMC7131020,5.96e-05,"FIG. 1. Northern blots showing mono- and polycistronic TRTVmRNAs containtng M and F gene seque-Ices. RNA was extractedfrom TRTV-Infected (lanes 3. 5, 7, and 9) a Id mock-infected (lanes 2,4, 6, and 8) Vero cells and electrophoresed in a denaturing agarosegel before (lanes 2, 3, 6, and 7) and after (lanes 4, 5, 8, and 9)poly(A)+ selection. The poly(A)+-selected RNA migrated slightlyfaster than the nonselected RNA. After transfer to nitrocellulose theRNAs were probed with a TRTV F-specific (lanes 2-5) and M-specific(lanes 6-9) DNA probe. Lane 1 contains IBV mRNAs, the sizes (kilo-bases) of which are shown on the left. The monocistronic M and FmRNAs are identified by M and F, respectively, and dicrstronic M-FmRNA by MF. The positions of other polycistronic mRNAs and ge-nome-sized RNA are shown by filled circles,",doi.org/10.1016/0042-6822(92)90007-C,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7131020_1\4_1.jpg
PMC7131020,5.96e-05,"Fig. 3) will appear in the DDBJ, EMBL, and GenbankNucleotide Sequence Databases underAccession No.X58639.",doi.org/10.1016/0042-6822(92)90007-C,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7131020_1\4_2.jpg
PMC7131020,5.96e-05,"FIG. 4. Mapping of the 5Ã¢Â€Â™end of the (A) M mRNA and (6) F mRNA byprimer extension. (A) An end-labeled 25-mer oligonucleotide whose5Ã¢Â€Â™ end corresponded to nucleotide position 79 in Fig. 3 was used toprime extension on M mRNA present in poly(A)+-selected TRTVin-fected Vero cell RNA. The same end-labeled oligonucleotide wasused to prime a sequencing reaction using pBluescript containinginsert MF36 as substrate. All reactions were analyzed in a 6% acryl-amide sequencing gel. Primer extension of the M mRNA produced aproduct which migrated as a double band (right hand side fourlanes), the lower of which comigrated with the first nucleotide G inthe sequence GGGACAAGU derived from pBluescript containingclone MF36. (B) A 25-mer, end-labeled oligonucleotide whose 5Ã¢Â€Â™endwas located 78 nucleotides from the presumed start of the F mRNAwas used to prime extension on F mRNA present in poly(A)+-se-lected RNA. The oligonucleotide was also used to prime a sequenc-ing reaction using pBluescript containing insert MF37 as substrate.Primer extension of the F mRNA produced a product which migratedas a double band (right hand side four lanes), the lower of whichcomigrated with the first base of the sequence GGGACAAGU. Thisconfirmed that the sequence GGGACAAGU was at the start of boththe M and the F mRNAs.",doi.org/10.1016/0042-6822(92)90007-C,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7131020_1\7_1.jpg
PMC7131020,5.96e-05,"FIG. 5. Confirmation of the TRTV partial gene order 3Ã¢Â€Â™-M-F-5Ã¢Â€Â™. ThePCR was used with various combinations of oligonucleotides A-D(see Fig. 2) to prime DNA synthesis using TRTV strain 3BV genomicRNA as template. The products were visualized in an ethidium bro-mide-stained agarose gel. (b,c) Oligonucleotides A (sequence nearthe 5Ã¢Â€Â™ end of the M gene) and B (near the 3Ã¢Â€Â™ end of the F gene); (d,e)oligonucleotides C (near the 5Ã¢Â€Â™ end of the gene upstream from the Mgene) and D (near the 3Ã¢Â€Â™ end of the M gene); (f.g,h) oligonucleotidesC and B; (g) the RNA had been extracted from virions derived aftervirus passage at very low m.o.i.; (h) the RNA was from tracheal organculture-passaged TRTV strain S&2381/88. The PCR polymerizationtime was either 5 min (b,d) or 15 min (c,e,f,g,h). Lanes (a) and (i)contained a HindIll digest of lambda DNA and a Haelll digest of4X174 DNA (BRL); the sizes in kilobases, of five of the DNA frag-ments are shown.",doi.org/10.1016/0042-6822(92)90007-C,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7131020_1\7_2.jpg
PMC7131020,5.96e-05,"FIG. 5. Confirmation of the TRTV partial gene order 3Ã¢Â€Â™-M-F-5Ã¢Â€Â™. ThePCR was used with various combinations of oligonucleotides A-D(see Fig. 2) to prime DNA synthesis using TRTV strain 3BV genomicRNA as template. The products were visualized in an ethidium bro-mide-stained agarose gel. (b,c) Oligonucleotides A (sequence nearthe 5Ã¢Â€Â™ end of the M gene) and B (near the 3Ã¢Â€Â™ end of the F gene); (d,e)oligonucleotides C (near the 5Ã¢Â€Â™ end of the gene upstream from the Mgene) and D (near the 3Ã¢Â€Â™ end of the M gene); (f.g,h) oligonucleotidesC and B; (g) the RNA had been extracted from virions derived aftervirus passage at very low m.o.i.; (h) the RNA was from tracheal organculture-passaged TRTV strain S&2381/88. The PCR polymerizationtime was either 5 min (b,d) or 15 min (c,e,f,g,h). Lanes (a) and (i)contained a HindIll digest of lambda DNA and a Haelll digest of4X174 DNA (BRL); the sizes in kilobases, of five of the DNA frag-ments are shown.",doi.org/10.1016/0042-6822(92)90007-C,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7131020_1\7_3.jpg
PMC7131020,5.96e-05,"FIG. 5. Confirmation of the TRTV partial gene order 3Ã¢Â€Â™-M-F-5Ã¢Â€Â™. ThePCR was used with various combinations of oligonucleotides A-D(see Fig. 2) to prime DNA synthesis using TRTV strain 3BV genomicRNA as template. The products were visualized in an ethidium bro-mide-stained agarose gel. (b,c) Oligonucleotides A (sequence nearthe 5Ã¢Â€Â™ end of the M gene) and B (near the 3Ã¢Â€Â™ end of the F gene); (d,e)oligonucleotides C (near the 5Ã¢Â€Â™ end of the gene upstream from the Mgene) and D (near the 3Ã¢Â€Â™ end of the M gene); (f.g,h) oligonucleotidesC and B; (g) the RNA had been extracted from virions derived aftervirus passage at very low m.o.i.; (h) the RNA was from tracheal organculture-passaged TRTV strain S&2381/88. The PCR polymerizationtime was either 5 min (b,d) or 15 min (c,e,f,g,h). Lanes (a) and (i)contained a HindIll digest of lambda DNA and a Haelll digest of4X174 DNA (BRL); the sizes in kilobases, of five of the DNA frag-ments are shown.",doi.org/10.1016/0042-6822(92)90007-C,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7131020_1\7_4.jpg
PMC7131020,5.96e-05,"FIG. 6. Hydropathy profiles for the (A) TRTV and (B) RS virus Mproteins. Positive values indicate hydrophobic regions and negativevalues indicate hydrophilic regions. The midpoint line represents agrand average of the hydropathy of the amino acid composition of alarge number of sequenced proteins (Kyte and Doolittle, 1982). Eachpoint on the profile represents the average hydropathy of a span offive residues.",doi.org/10.1016/0042-6822(92)90007-C,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7131020_1\8_1.jpg
PMC7133225,5.8099999999999996e-05,Figure 7. Potential Tertiary RNA Structures at Other (-1) Frameshift Sites,doi.org/10.1016/0092-8674(89)90124-4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7133225_1\10_1.jpg
PMC7133225,5.8099999999999996e-05,Figure 1. Ribosomal Frameshtfttng In Vrtroand In Vivo,doi.org/10.1016/0092-8674(89)90124-4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7133225_1\3_1.jpg
PMC7133225,5.8099999999999996e-05,Figure 2. Upstream Components of the IBVFrameshifting Signal,doi.org/10.1016/0092-8674(89)90124-4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7133225_1\4_1.jpg
PMC7133225,5.8099999999999996e-05,Figure 3. Downstream Components of the IBV Frameshifting Signal,doi.org/10.1016/0092-8674(89)90124-4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7133225_1\5_1.jpg
PMC7133225,5.8099999999999996e-05,Figure 4. A Tertiary RNA Structure Forms in the IBV Frameshift Region,doi.org/10.1016/0092-8674(89)90124-4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7133225_1\6_1.jpg
PMC7133225,5.8099999999999996e-05,Figure 5. Proposed Folding of the RNA at the IBV Frameshift Region:Formation of an RNA Pseudoknot,doi.org/10.1016/0092-8674(89)90124-4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7133225_1\7_1.jpg
PMC7133225,5.8099999999999996e-05,Figure 6. The Effect on Frameshifting Effi-,doi.org/10.1016/0092-8674(89)90124-4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7133225_1\8_1.jpg
PMC7135038,5.05e-05,Figure: Timeline of early stages of 2019-nCoV outbreak2019-nCoV=2019 novel coronavirus.,doi.org/10.1016/S0140-6736(20)30185-9,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7135038_1\3_1.jpg
PMC7135076,0.000146556,"Figure: Chest x-rays and chest CTs of three patientsCase 1: chest x-ray was obtained on Jan 1 (1A). The brightness of both lungs was diffusely decreased, showinga large area of patchy shadow with uneven density. Tracheal intubation was seen in the trachea and the heartshadow outline was not clear. The catheter shadow was seen from the right axilla to the mediastinum. Bilateraldiaphragmatic surface and costal diaphragmatic angle were not clear, and chest x-ray on Jan 2 showed worsestatus (1B). Case 2: chest x-ray obtained on Jan 6 (2A). The brightness of both lungs was decreased and multiplepatchy shadows were observed; edges were blurred, and large ground-glass opacity and condensation shadowswere mainly on the lower right lobe. Tracheal intubation could be seen in the trachea. Heart shadow roughlypresents in the normal range. On the left side, the diaphragmatic surface is not clearly displayed. The right side ofthe diaphragmatic surface was light and smooth and rib phrenic angle was less sharp. Chest x-ray on Jan 10showed worse status (2B). Case 3: chest CT obtained on Jan 1 (3A) showed mass shadows of high density in bothlungs. Bright bronchogram is seen in the lung tissue area of the lesion, which is also called bronchoinflation sign.Chest CT on Jan 15 showed improved status (3B).",doi.org/10.1016/S0140-6736(20)30211-7,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7135076_1\6_1.jpg
PMC7140172,5.550000000000001e-05,"Figure 1: Genome structure of SARS-CoVNSP=Non-structural proteins. S=spike protein. E=small envelop protein. N=nucleocapsid. M=Membrane protein. MHV=murine hepatitis virus. MD=metalbinding. 3CL-PRO=3C-like proteinase. The top scale shows the approximate nucleotide position along SARS-CoV genome (golden bar) determined from theSingapore isolate SIN2500. The arrows on top of the genome bar map the locations where nucleotide sequence variations, present in two or moreisolates, were detected. The two open triangles point to the locations where the two multi-nucleotide deletions occurred. The SARS genome is predicted toencode 23 putative mature proteins (blue bars). The arrows on top of the protein bars indicate the location of aminoacid changes.",doi.org/10.1016/S0140-6736(03)13414-9,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7140172_1\4_1.jpg
PMC7140172,5.550000000000001e-05,"Figure 2: Homology of SARS-CoV genome sequence (SIN2500) to other coronavirusesA heat map created by comparing overlapping fragments of the SARS-CoV genome sequence against a database of coronavirus sequences. The SARSfragments are plotted along the horizontal axis in the order they appear in the genome, and the other coronaviruses are plotted vertically. The brightness ofa pixel corresponds to the strength of the match between a SARS fragment and a coronavirus genome; the smaller the p value, the lighter the pixel.",doi.org/10.1016/S0140-6736(03)13414-9,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7140172_1\4_2.jpg
PMC7140172,5.550000000000001e-05,"Figure 3: Sequence comparisons of the 14 available SARS-CoV genomesOnly those variant sequences (red) that were present in at least two independent sequences are shown. See webappendix2 for complete list of all variantnucleotides. The frequency of appearance of each variant nucleotide is presented. Highlighted in yellow are four sequence positions that define two distinctgenotypic variants of SARS-CoV. The position of each nucleotide is based upon the URBANI SARS-CoV sequence and the corresponding encoded protein oruncharacterised open reading frames (ORF) are indicated. The effect, if any, on the encoded aminoacid (AA) is described. Nucleotides that are missing (-) orambiguous (N) in the genome sequences are indicated and the length of each genome sequence is given. The patientsÃ¢Â€Â™ countries of origin and association ofpatient with Hotel M are provided for all viral genome sequences, and the relative order of transmission is provided for the Singapore cases.",doi.org/10.1016/S0140-6736(03)13414-9,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7140172_1\5_1.jpg
PMC7140172,5.550000000000001e-05,Figure 4: Molecular relations between the 14 SARS-CoVisolatesPhylogenetic trees obtained by applying PAUP* to complete genomesequences of all 14 SARS-CoV samples. The tree was built with onlysequence variants that occurred at least twice.,doi.org/10.1016/S0140-6736(03)13414-9,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7140172_1\6_1.jpg
PMC7140172,5.550000000000001e-05,"Figure 5: Clinical relations between the 14 SARS-CoV isolatesThe routes of transmissions are shown for the 14 viral isolates that have been sequenced, indicatedwith solid boxes. Solid arrows=routes of transmission from Hotel M are known be direct. Brokenarrow=direct relation information is not available. Patient A is the Hong Kong index patient whotravelled from Guangdong to Hong Kong and transmitted SARS to others at Hotel M, who thentravelled to Singapore, Canada, and Vietnam, thus becoming index cases in those countries.15 Theroutes of transmission from Guangdong are unknown and shown as dotted arrows. *Dashed boxesare routes of transmission that are uncertain.",doi.org/10.1016/S0140-6736(03)13414-9,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7140172_1\6_2.jpg
PMC7158907,5.7700000000000007e-05,"Figure 1: Recombinant NP and RBD of spike protein used for EIA(A) Sodium dodecyl sulphate-polyacrylamide gel electrophoresis showing purity of His-tagged RBD of spikeprotein (lane 1) and His-tagged NP (lane 3). Lane 2 is protein molecular weight marker. (B) Western-blot analysisof RBD of spike protein (lane 1) and NP (lane 2) using anti-His monoclonal antibody. Positive control (NP of severefever with thrombocytopenia syndrome virus) is in lane 3 and negative control (GST-tagged protein) is in lane 4.(C) Western-blot confirmatory assay of NP using patientÃ¢Â€Â™s serum. Anti-His monoclonal antibody in lane 1, negativepatient serum in lane 2, serum samples from a patient with COVID-19 obtained during the acute phase of illness(5 days after symptom onset) in lane 3 (dilution 1 part to 100 parts) and during the convalescent phase (18 daysafter symptom onset) in lane 4 (dilution 1 part to 3200 parts), lane 5 (1 part to 1600 parts), and lane 6 (1 part to800 parts). (D) Western-blot confirmatory assay with spike protein RBD using serum samples from patients withCOVID-19. Anti-His monoclonal antibody in lane 1, negative patient serum in lane 2, serum from two patientswith COVID-19 in lanes 3 and 4 (dilution 1 part to 100 parts). NP=nucleoprotein. RBD=receptor-binding domain.His=polyhistidine. GST=glutathione S-transferase. COVID-19=coronavirus disease 2019.",doi.org/10.1016/S1473-3099(20)30196-1,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7158907_1\4_1.jpg
PMC7158907,5.7700000000000007e-05,Figure 3: Relation between viral load and age or disease severityCorrelation between age and peak viral load (A). Comparison of initial (B) and peak (C) viral load between severe and mild cases. Comparison of initial (D) andpeak (E) viral load between patients with comorbidities and those without comorbidities.,doi.org/10.1016/S1473-3099(20)30196-1,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7158907_1\7_1.jpg
PMC7158907,5.7700000000000007e-05,"Figure 4: Temporal profiles of serum IgM and IgG against NP and spike protein RBD, as ascertained by EIAEach line represents an individual patient. NP=nucleoprotein. RBD=receptor-binding domain. OD450Ã¢Â€Â“620=optical density at 450Ã¢Â€Â“620 nm.",doi.org/10.1016/S1473-3099(20)30196-1,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7158907_1\8_1.jpg
PMC7158907,5.7700000000000007e-05,Figure 5: Correlation between MN antibody titres and anti-NP or anti-RBD IgG or IgMOD450Ã¢Â€Â“620=optical density at 450Ã¢Â€Â“620 nm. MN=microneutralisation. NP=nucleoprotein. RBD=receptor-binding domain.,doi.org/10.1016/S1473-3099(20)30196-1,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7158907_1\9_1.jpg
PMC7158942,7.01e-05,Figure: Screening profile,doi.org/10.1016/S0140-6736(20)30460-8,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7158942_1\3_1.jpg
PMC7159028,7.2e-05,"Figure 5. Nidoviruses encodehomologs of cellular enzymesinvolved in RNA processing.(A) The cellular pathways for pro-cessing of pre-U16 snoRNA andpre-tRNA splicing are summarized,with relevant enzymatic activitiesindicated. For details, see the text.Homologs of the highlightedenzymes have been identiÃ¯Â¬Âed innidoviruses (see also Figure 1 andthe text). (B) Table summarizingthe conservation of homologs ofthe cellular enzymes presumablyinvolved in RNA processing inSARS-CoV and different nidovirusgroups.",doi.org/10.1016/S0022-2836(03)00865-9,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7159028_1\11_1.jpg
PMC7159028,7.2e-05,"Figure 1. Overview of the SARS-CoV genome organization and expression. Comparison of the genome organiz-ations of SARS-CoV and bovine coronavirus (BCoV). The replicase genes are depicted, with ORF1a, ORF1b, and ribo-somal frameshift site indicated. Arrows represent sites in the corresponding replicase polyproteins that are cleavedby papain-like proteinases (orange) or the 3C-like cysteine proteinase (blue). Cleavage products are provisionallynumbered nsp1Ã¢Â€Â“ nsp16 (see also Table 1). In the 30-terminal part of the genomes, homologous structural protein genesare indicated in matching colors. Close-ups of two regions with major differences are shown (and see the text). In theN-terminal half of replicase ORF1a, SARS-CoV lacks one of the PLpro domains (indicated in orange/green in BCoV)and contains a unique insertion (SUD). In the region with structural and accessory protein genes, the location of thebody TRSs involved in subgenomic RNA synthesis are indicated with red boxes (see Figure 3 and Hofmann et al.76).The bottom part of the Figure illustrates which parts of the genome are conserved in the genus Coronavirus and inthe order Nidovirales (the ORF1a sequence of toroviruses, which largely remains to be sequenced, could not beincluded). Furthermore, it is indicated for which domains homologs have been identiÃ¯Â¬Âed in other RNA viruses andthe cellular world. Enzymes for which structural data are available are shown in blue. SUD, SARS-CoV uniquedomain; PLpro, papainlike cysteine proteinase; 3CLpro, 3C-like cysteine proteinase; TM, transmembrane domain;ADRP, adenosine diphosphate-ribose 100-phosphatase; ExoN, 30-to-50 exonuclease; CLpro, chymotrypsin-like proteinase;RdRp, RNA-dependent RNA polymerase; HEL1, superfamily 1 helicase; XendoU, (homolog of) poly(U)-speciÃ¯Â¬Âcendoribonuclease; 20-O-MT, S-adenosylmethionine-dependent ribose 20-O-methyltransferase; CPD, cyclic phospho-diesterase. Domains Ac, X, and Y are described by Ziebuhr et al.32 and Gorbalenya et al.47",doi.org/10.1016/S0022-2836(03)00865-9,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7159028_1\3_1.jpg
PMC7159028,7.2e-05,"Figure 2. Phylogenetic analysis of coronavirusreplicase genes. SARS-CoV replicase ORF1b amino acidsequences (Entrez Genomes accession numberNC_004718 (AY274119)) were compared with those fromviruses representing the three coronavirus subgroupsand the genus Torovirus. Group 1: transmissible gastro-enteritis virus (TGEV), NC_002306; human coronavirus229E (HCoV-229E), NC_002645; porcine epidemicdiarrhea virus (PEDV), NC_003436. Group 2: mousehepatitis virus A59 (MHV-A59), NC_001846; bovine cor-onavirus (BCoV-Lun) AF391542. Group 3: infectiousbronchitis virus (IBV), strains Beaudette (NC_001451)and LX4 (AY223860). Torovirus: equine torovirus(EToV), X52374. A multiple protein alignment of thesesequences was generated with the help of the Clus-talX1.82 program65 and was adjusted manually. Tworegions of poor conservation were removed from thealignment, which was converted subsequently into thenucleotide form. All columns containing gaps wereremoved. The resulting alignment contains the followingSARS-CoV sequences fused: 13,623Ã¢Â€Â“ 13,859, 14,310Ã¢Â€Â“18,857 and 20,076 Ã¢Â€Â“ 21,482. It included 5487 characterswith 3207 of them being parsimony-informative. Usingthe PAUP program (version 4.0.0d55) and parsimony cri-terion, an exhaustive tree search of the 135,135 evaluatedtrees identiÃ¯Â¬Âed the best tree having a score of 10,927 andthe second best tree having a score of 10,964; the worsttree had a score of 13,611. A total of 1000 bootstrap trialswere conducted using the parsimony criterion and abranch-and-bound search to generate a bootstrap 50%majority-rule consensus tree. The frequency of occur-rence of particular bifurcations in bootstraps is indicatedat the nodes. Similar trees with similar high bootstrapsupport above 960 were obtained using the NJ methodthat was applied to distance matrices obtained for eithernucleotide or amino acid alignments (not shown).",doi.org/10.1016/S0022-2836(03)00865-9,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7159028_1\6_1.jpg
PMC7159028,7.2e-05,"Figure 3. SARS-CoV subgenomic mRNA synthesis. (A) Organization of ORFs in the 30 end of the SARS-CoV genomewith predicted leader and body TRSs indicated by small boxes. The subgenomic mRNAs resulting from the use ofthese TRSs for leader-to-body fusion are depicted below, with mRNAs predicted to be functionally bicistronicindicated with an asterisk ( p ). (B) Hybridization analysis of intracellular viral RNA from Vero cells infected withSARS-CoV, Frankfurt-1 (Fr) and HKU-39849 (HK) isolates. See Materials and Methods for technical details. Oligo-nucleotides complementary to sequences from the SARS-CoV leader sequence and to a region in the genomic 30 endboth recognized a set of nine RNA species (the genome (RNA1) and eight subgenomic RNAs) conÃ¯Â¬Ârming the presenceof common 50 and 30 sequences. RNA from Vero cells infected with avian infectious bronchitis virus (IBV), whichproduces only Ã¯Â¬Âve subgenomic mRNAs of known sizes41 was run in the same gel and used as a size marker.(C) Model for nidovirus subgenomic RNA synthesis by discontinuous extension of minus strands.19,39 Whereasgenome replication relies on continuous minus strand synthesis (antigenome), subgenomic minus strands would beproduced by attenuation of nascent strand synthesis at a body TRS (red bar), followed by translocation of the nascentstrand to the leader TRS in the genomic template. Following base-pairing between the body TRS complement at the30 end of the minus strand and the leader TRS, RNA synthesis would resume to complete the subgenomic minusstrand that would then serve as template for the transcription of subgenomic mRNAs.",doi.org/10.1016/S0022-2836(03)00865-9,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7159028_1\7_1.jpg
PMC7159028,7.2e-05,"Figure 4. Sequence alignments of protein families that include cellular enzymes involved in RNA processing andtheir nidovirus homologs. Our in-depth comparative sequence analysis (see Materials and Methods) revealed astatistically signiÃ¯Â¬Âcant relationship between functionally uncharacterized proteins (domains) of nidoviruses, including",doi.org/10.1016/S0022-2836(03)00865-9,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7159028_1\9_1.jpg
PMC7159086,8.190000000000001e-05,"Figure 5: Phylogenetic analysis and homology modelling of the receptor-binding domain of the 2019-nCoV,SARS-CoV, and MERS-CoV(A) Phylogenetic analysis of the receptor-binding domain from various betacoronaviruses. The star highlights2019-nCoV and the question marks means that the receptor used by the viruses remains unknown. Structuralcomparison of the receptor-binding domain of SARS-CoV (B), 2019-nCoV (C), and MERS-CoV (D) binding totheir own receptors. Core subdomains are magenta, and the external subdomains of SARS-CoV, 2019-nCoV,and MERS CoV are orange, dark blue, and green, respectively. Variable residues between SARS-CoV and 2019-nCoVin the receptor-binding site are highlighted as sticks. CoV=coronavirus. 2019-nCoV=2019 novel coronavirus.SARS-CoV=severe acute respiratory syndrome coronavirus. MERS=Middle East respiratory syndrome coronavirus.",doi.org/10.1016/S0140-6736(20)30251-8,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7159086_1\10_1.jpg
PMC7159086,8.190000000000001e-05,"Figure 1: Sequence comparison and genomic organisation of 2019-nCoV(A) Sequence alignment of eight full-length genomes of 2019-nCoV, 29Ã¢Â€Â‰829 base pairs in length, with a few nucleotides truncated at both ends of the genome.(B) Coding regions of 2019-nCoV, bat-SL-CoVZC45, bat-SL-CoVZXC21, SARS-CoV, and MERS-CoV. Only open reading frames of more than 100 nucleotides areshown. 2019-nCoV=2019 novel coronavirus. SARS-CoV=severe acute respiratory syndrome coronavirus. MERS-CoV=Middle East respiratory syndrome coronavirus.",doi.org/10.1016/S0140-6736(20)30251-8,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7159086_1\6_1.jpg
PMC7159086,8.190000000000001e-05,Figure 2: Sequence identity between the consensus of 2019-nCoV and representative betacoronavirus genomes(A) Sequence identities for 2019-nCoV compared with SARS-CoV GZ02 (accession number AY390556) and the bat SARS-like coronaviruses bat-SL-CoVZC45(MG772933) and bat-SL-CoVZXC21 (MG772934). (B) Similarity between 2019-nCoV and related viruses. 2019-nCoV=2019 novel coronavirus. SARS-CoV=severeacute respiratory syndrome coronavirus.,doi.org/10.1016/S0140-6736(20)30251-8,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7159086_1\7_1.jpg
PMC7159086,8.190000000000001e-05,Figure 3: Phylogenetic analysis of full-length genomes of 2019-nCoV and representative viruses of the genus Betacoronavirus2019-nCoV=2019 novel coronavirus. MERS-CoV=Middle East respiratory syndrome coronavirus. SARS-CoV=severe acute respiratory syndrome coronavirus.,doi.org/10.1016/S0140-6736(20)30251-8,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7159086_1\8_1.jpg
PMC7159086,8.190000000000001e-05,Figure 4: Specific amino acid variations among the spike proteins of the subgenus sarbecovirusViruses are ordered by the tree topology (as shown in figure 3) from top to bottom. One-letter codes are used for amino acids. CoV=coronavirus. 2019-nCoV=2019 novel coronavirus. SARS=severeacute respiratory syndrome. *Bat-derived SARS-like viruses that can grow in human cell lines or in mice. Ã¢Â€Â Bat-derived SARS-like viruses without experimental data available.,doi.org/10.1016/S0140-6736(20)30251-8,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7159086_1\9_1.jpg
PMC7159086,8.190000000000001e-05,Figure S2. Phylogenetic analysis of separate gene regions of 2019-nCoV and representative viruses of the subgenus Sarbecoronavirus.,doi.org/10.1016/S0140-6736(20)30251-8,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7159086_2\5_1.jpg
PMC7159086,8.190000000000001e-05,Figure S3. Sequence alignment of RBDs from 2019-nCoV related beta-CoVs.,doi.org/10.1016/S0140-6736(20)30251-8,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7159086_2\6_1.jpg
PMC7159286,7.240000000000001e-05,Figure 4: Genome organisation of 2019-nCoV and the amino acid identities of different subunits and domainsof the Spike between human 2019-nCoV strains (HKU-SZ-002a and HKU-SZ-005b) and bat-SL-CoV-ZC452ÃŠÂ¹-O-MT=2ÃŠÂ¹-O-ribose methyltransferase. 3CLpro=3C-like protease. DMV=double-membrane vesicles. E=envelope.EndoU=endoribonuclease. ESD=external subdomain. ExoN=exonuclease. FP=fusion peptide. Hel=helicase.HR1=heptad repeat 1. HR2=heptad repeat 2. M=membrane. N=nucleocapsid. NSP=non-structural protein.NTD=N-terminal domain. ORF=open reading frame. PLpro=papain-like protease. RBD=receptor binding domain.S=spike. S1=subunit 1. S2=subunit 2. SP=signal peptide. TM=transmembrane domain.,doi.org/10.1016/S0140-6736(20)30154-9,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7159286_1\10_1.jpg
PMC7159286,7.240000000000001e-05,"Figure 1: Chronology ofsymptom onset of theShenzhen family cluster andtheir contacts in WuhanDates filled in red are the dateson which patients 1Ã¢Â€Â“6 hadclose contacts with theirrelatives (relatives 1Ã¢Â€Â“5).Dates filled in yellow are thedates on which patients 3Ã¢Â€Â“6stayed with patient 7.The boxes with an internal redcross are the dates on whichpatients 1 and 3 or relatives 1,2, and 3 had stayed overnight(white boxes) at or had visited(blue boxes) the hospital inwhich relative 1 was admittedfor febrile pneumonia.The information of relatives1Ã¢Â€Â“5 was provided by patient 3.No virological data wereavailable.Relative 4 (sister of relative 3) 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15",doi.org/10.1016/S0140-6736(20)30154-9,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7159286_1\4_1.jpg
PMC7159286,7.240000000000001e-05,"Figure 2: Representative images of the thoracic CT scans showing multifocal ground-glass changes in thelungs of patient 1 (A), patient 2 (B), patient 3 (C), and patient 5 (D)",doi.org/10.1016/S0140-6736(20)30154-9,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7159286_1\6_1.jpg
PMC7159286,7.240000000000001e-05,"Figure 3: Phylogenetic trees of genetic sequences(A) Amplicon fragments of RNA-dependent RNA polymerase of patients 1, 2, 4, 5, and 7. (B) Amplicon fragmentsof Spike gene of patients 1, 2, 4, 5, and 7. (C) The full genome sequences of strains from patients 2 and 5. Red textindicates the coronavirus (CoV) strains detected in the patients in the present study. 2019-nCoV is 2019 novelcoronavirus. HKU-SZ-001 refers to the strain detected in the nasopharyngeal swab of patient 1; HKU-SZ-002arefers to strain detected in the nasopharyngeal swab of patient 2; HKU-SZ-002b refers to strain detected in theserum sample of patient 2; HKU-SZ-004 refers to the strain detected in the nasopharyngeal swab of patient 4;HKU-SZ-005 refers to the strain detected in the throat swab of patient 5; HKU-SZ-005b refers to the strain detectedin the sputum sample of patient 5; HKU-SZ-007a refers to the strain detected in the nasopharyngeal swab ofpatient 7; HKU-SZ-007b refers to the strain detected in the throat swab of patient 7; and HKU-SZ-007c refers to thestrain detected in the sputum sample of patient 7 (appendix p 6). The NCBI GenBank accession numbers of thegenome sequences are MN938384 (HKU-SZ-002a), MN975262 (HKU-SZ-005b), MG772934 (Bat SL-CoV ZXC21),MG772933 (Bat SL-CoV ZC45), AY274119 (hSARS-CoV Tor2), AY278491 (SARS coronavirus HKU-39849),AY278488 (hSARS-CoV BJ01), AY390556 (hSARS-CoV GZ02), AY515512 (Paguma SARS CoV HC/SZ/61/03),KY417146 (Bat SL-CoV Rs4231), KC881005 (Bat SL-CoV RsSHC014), KC881006 (Bat SL-CoV Rs3367), MK211377(Bat CoV YN2018C), MK211378 (Bat CoV YN2018D), KY417149 (Bat SL-CoV Rs4255), FJ588686(Bat SL-CoV Rs672), NC014470 (Bat SARS-related CoV BM48-31), EF065513 (Bat CoV HKU9-1), AY391777(hCoV OC43), NC006577 (hCoV HKU1), NC019843 (hMERS CoV), NC009020 (Bat CoV HKU5-1), NC009019(Bat CoV HKU4-1), and NC002645 (hCoV 229E).",doi.org/10.1016/S0140-6736(20)30154-9,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7159286_1\9_1.jpg
PMC7159299,0.000295025,"Figure 1: Date of illness onset and age distribution of patients with laboratory-confirmed 2019-nCoVinfection(A) Number of hospital admissions by age group. (B) Distribution of symptom onset date for laboratory-confirmedcases. The Wuhan local health authority issued an epidemiological alert on Dec 30, 2019, and closed the Huananseafood market 2 days later.",doi.org/10.1016/S0140-6736(20)30183-5,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7159299_1\4_1.jpg
PMC7159299,0.000295025,Figure 2: Timeline of 2019-nCoV cases after onset of illness,doi.org/10.1016/S0140-6736(20)30183-5,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7159299_1\6_1.jpg
PMC7159299,0.000295025,Figure 3: Chest CT images,doi.org/10.1016/S0140-6736(20)30183-5,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7159299_1\8_1.jpg
PMC7160442,6.59e-05,"FigureReported COVID-19 cases per 100,000 population by country over 100 days, 30 December 2019Ã¢Â€Â“8 April 2020 (n =1,391,890)",doi.org/10.2807/1560-7917.ES.2020.25.14.2000550,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7160442_1\2_1.jpg
PMC7164771,6.04e-05,Fatigue,doi.org/10.1016/S2213-2600(20)30076-X,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7164771_1\2_1.jpg
PMC7164771,6.04e-05,"Figure 1: Timeline of disease course according to days from initial presentation of illness and days from hospital admission, from Jan 8Ã¢Â€Â“27, 2020SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.",doi.org/10.1016/S2213-2600(20)30076-X,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7164771_1\2_2.jpg
PMC7164771,6.04e-05,"Figure 2: Pathological manifestations of right (A) and left (B) lung tissue, liver tissue (C), and heart tissue (D)in a patient with severe pneumonia caused by SARS-CoV-2SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.",doi.org/10.1016/S2213-2600(20)30076-X,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7164771_1\3_1.jpg
PMC7164771,6.04e-05,Fig. S2 Phenotypic analysis of circulating T cells. (A) Both CD4 and CD8 T cells were hyper activated.,doi.org/10.1016/S2213-2600(20)30076-X,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7164771_2\4_1.jpg
PMC7167720,5.36e-05,Figure 1. Normal lung tissue: overview (A) and larger magniÃ¯Â¬Âcation (B). Positive staining for ACE2 is clearly present on alveolarepithelial cells (arrow) and capillary endothelium (arrow-head). Fibrotic lung tissue (C) and larger magniÃ¯Â¬Âcation (D). Positivestaining for ACE2 is clearly present on type II cells (arrow). Cultured lung type II alveolar epithelial cells (A549) are stronglypositive for ACE2 (E). Control section stained with anti-ACE2 in the presence of the synthetic ACE2 peptide shows no stainingof lung tissue (F),doi.org/10.1002/path.1570,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7167720_1\3_1.jpg
PMC7167720,5.36e-05,"Figure 2. Overview of oral mucosa (A). Strong staining is observed in vascular endothelium (arrow) and vascular smooth musclecells (arrow-head). Granular ACE2 staining is present in the basal layer of the epithelium. In the small intestine (ileum) (B), strongstaining can be seen in the villous brush border (arrow), the muscularis mucosae (arrow-head), and the muscularis propria (star).In a larger magniÃ¯Â¬Âcation of the submucosa (C), strong staining is present in vascular endothelium (arrow) and vascular smoothmuscle cells (arrow-head). In a larger magniÃ¯Â¬Âcation of the villi (D), abundant staining is seen on the brush border of the enterocytes(arrow). In the colon (E), ACE2 staining is present in endothelium and vascular smooth muscle cells from the blood vessels(arrow-head) and in the muscular layers. Control section stained with anti-ACE2 in the presence of the synthetic ACE2 peptideshows no staining in the small intestine (ileum) (F)",doi.org/10.1002/path.1570,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7167720_1\4_1.jpg
PMC7167720,5.36e-05,"Figure 3. Skin tissue (A) with larger magniÃ¯Â¬Âcation (C, D). Staining is abundantly present in blood vessels/capillaries and in thebasal layer of the epidermis (arrow) and hair follicles (arrow-head). Eccrine glands also express ACE2 (B)",doi.org/10.1002/path.1570,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7167720_1\5_1.jpg
PMC7167720,5.36e-05,"Figure 4. In the brain (A), ACE2 is expressed only in endothelium (arrow) and vascular smooth muscle cells. In the liver (B),Kupffer cells, hepatocytes, and the endothelium of sinusoids are negative. Luminal staining in bile ducts is occasionally observed(arrow-head). Vascular endothelium (arrow) and smooth muscle cells are positive. In the spleen (C), ACE2 is not expressed incells of the immune system. Vascular and red pulp sinus endothelium is positive. In the kidney (D), ACE2 is present in glomerularvisceral (arrow) and parietal (arrow-head) epithelium, in the brush border (short arrow) and cytoplasm of proximal tubular cells,and in the cytoplasm of distal tubules and collecting ducts",doi.org/10.1002/path.1570,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7167720_1\6_1.jpg
PMC7211647,5.07e-05,"Figure. Temporal variation in ED visits (upper left), admissions to a regular Ã¯Â¬Â‚oor (upper right), admissions from the ED to the ICU(bottom left), and total number of invasive mechanical ventilations from the ED and previously admitted patients (bottom right).",doi.org/10.1016/j.a-1-1emergmed.2020.05.011,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7211647_1\5_1.jpg
PMC7211647,5.07e-05,Fatigue,doi.org/10.1016/j.a-1-1emergmed.2020.05.011,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7211647_1\9_1.jpg
PMC7268961,0.00010321299999999999,Figure 1: Simulated mean PK profile of HCQ in plasma in Chinese healthy,doi.org/10.1186/s13063-020-04446-4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7268961_2\73_1.jpg
PMC7268961,0.00010321299999999999,Figure 2: Simulated mean PK profile of HCQ in blood in Chinese healthy,doi.org/10.1186/s13063-020-04446-4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7268961_2\73_2.jpg
PMC7268961,0.00010321299999999999,Figure 3: Simulated mean PK profile of HCQ in lung in Chinese healthy populations.,doi.org/10.1186/s13063-020-04446-4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7268961_2\74_1.jpg
PMC7268961,0.00010321299999999999,Figure 4: Simulated mean PK profile of HCQ in plasma in Caucasian healthy,doi.org/10.1186/s13063-020-04446-4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7268961_2\74_2.jpg
PMC7268961,0.00010321299999999999,Figure 5: Simulated mean PK profile of HCQ in blood in Caucasian healthy,doi.org/10.1186/s13063-020-04446-4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7268961_2\75_1.jpg
PMC7268961,0.00010321299999999999,Figure 6: Simulated mean PK profile of HCQ in lung in Caucasian healthy,doi.org/10.1186/s13063-020-04446-4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7268961_2\75_2.jpg
PMC7268961,0.00010321299999999999,Figure 7: Simulated mean PK profile of HCQ in plasma in Caucasian renal injury,doi.org/10.1186/s13063-020-04446-4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7268961_2\76_1.jpg
PMC7268961,0.00010321299999999999,Figure 8: Simulated mean PK profile of HCQ in blood in Caucasian renal injury,doi.org/10.1186/s13063-020-04446-4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7268961_2\76_2.jpg
PMC7268961,0.00010321299999999999,Figure 9: Simulated mean PK profile of HCQ in lung in Caucasian renal injury,doi.org/10.1186/s13063-020-04446-4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7268961_2\77_1.jpg
PMC7270627,0.000185678,"Fatigue44 (23%)Diarrhoea9 (5%)Nausea or vomiting7 (4%)SOFA score2Ã‚Â·0 (1Ã‚Â·0Ã¢Â€Â“4Ã‚Â·0)qSOFA score1Ã‚Â·0 (0Ã‚Â·0Ã¢Â€Â“1Ã‚Â·0)CURB-65 score0Ã‚Â·0 (0Ã‚Â·0Ã¢Â€Â“2Ã‚Â·0)0Ã¢Â€Â“1141/188 (75%)232/188 (17%)3Ã¢Â€Â“515/188 (8%)Disease severity statusÃ‚Â·Ã‚Â·General72 (38%)Severe66 (35%)Critical53 (28%)Time from illness onset tohospital admission, days11Ã‚Â·0 (8Ã‚Â·0Ã¢Â€Â“14Ã‚Â·0)",doi.org/10.1016/S0140-6736(20)30566-3,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7270627_1\4_1.jpg
PMC7270627,0.000185678,Figure 1: Clinical courses of major symptoms and outcomes and duration of viral shedding from illness onset in patients hospitalised with COVID-19Figure shows median duration of symptoms and onset of complications and outcomes. ICU=intensive care unit. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. ARDS=acute respiratorydistress syndrome. COVID-19=coronavirus disease 2019.,doi.org/10.1016/S0140-6736(20)30566-3,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7270627_1\8_1.jpg
PMC7270627,0.000185678,"Figure 2: Temporal changes in laboratory markers from illness onset in patients hospitalised with COVID-19Figure shows temporal changes in d-dimer (A), lymphocytes (B), IL-6 (C), serum ferritin (D), high-sensitivitycardiac troponin I (E), and lactate dehydrogenase (F). Differences between survivors and non-survivors weresignificant for all timepoints shown, except for day 4 after illness onset for d-dimer, IL-6, and high-sensitivitycardiac troponin I. For serum ferritin (D), the median values after day 16 exceeded the upper limit of detection,as indicated by the dashed line. COVID-19=coronavirus disease 2019. IL-6=interleukin-6.",doi.org/10.1016/S0140-6736(20)30566-3,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7270627_1\9_1.jpg
PMC7273378,8.79e-05,Figure 1. Trial design,doi.org/10.1186/s13063-020-04420-0,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7273378_1\15_1.jpg
PMC7273378,8.79e-05,Figure 2.,doi.org/10.1186/s13063-020-04420-0,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7273378_1\27_1.jpg
PMC7276742,6.22e-05,Fatigueness of breath throat,doi.org/10.1002/uog.22088,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7276742_1\29_1.jpg
PMC7277789,6.56e-05,Figure 4. Cont.,doi.org/10.3390/biomedici-1es8050129,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7277789_1\11_1.jpg
PMC7277789,6.56e-05,Figure 4. EÃ¯Â¬Â€ects of quercetin and vitamin D on expression of genes encoding human prey proteins,doi.org/10.3390/biomedici-1es8050129,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7277789_1\12_1.jpg
PMC7277789,6.56e-05,Figure 5. Cont.,doi.org/10.3390/biomedici-1es8050129,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7277789_1\13_1.jpg
PMC7277789,6.56e-05,Figure 5. EÃ¯Â¬Â€ects of estradiol on expression of genes encoding human prey proteins of SARS-CoV-2.(A) Estradiol alters the expression of 203 of 332 (61%) of genes encoding human prey proteins for 26of 27 (96%) of SARS-CoV-2 proteins. Percent values refer to the fractions of targets aÃ¯Â¬Â€ected by theestradiol based on gene expression proÃ¯Â¬Âling experiments. Both downregulated and upregulated geneswere scored assuming that expression changes would alter the stoichiometry of viral protein/human,doi.org/10.3390/biomedici-1es8050129,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7277789_1\14_1.jpg
PMC7277789,6.56e-05,Figure 6. Cont.,doi.org/10.3390/biomedici-1es8050129,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7277789_1\15_1.jpg
PMC7277789,6.56e-05,Figure 6. Cont.,doi.org/10.3390/biomedici-1es8050129,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7277789_1\16_1.jpg
PMC7277789,6.56e-05,"Figure 6. EÃ¯Â¬Â€ects of the VDR gene, vitamin D, and quercetin on pathways and genes aÃ¯Â¬Â€ecting thenewly emerged SARS-CoV-2 virus-related host targets. (A) EÃ¯Â¬Â€ects of the VDR gene, vitamin D, andquercetin on repressors of the ACE expression. (B). EÃ¯Â¬Â€ects of the VDR gene, vitamin D, and quercetin onactivators of the ACE expression. (C). EÃ¯Â¬Â€ects of the VDR gene, vitamin D, and quercetin on repressorsof the ACE expression reÃ¯Â¬Â‚ecting GATA5 inhibitory eÃ¯Â¬Â€ects on SFTPC expression in the mouse lungs. (D).EÃ¯Â¬Â€ects of the VDR gene, vitamin D, and quercetin on activators of the ACE expression reÃ¯Â¬Â‚ecting the celltype-speciÃ¯Â¬Âc eÃ¯Â¬Â€ects of vitamin D and quercetin: vitamin D-induced activation of the INSIG1 expressionin human bronchial smooth muscle cells and quercetin-induced activation of the INSIG1 expression inhuman intestinal cells.",doi.org/10.3390/biomedici-1es8050129,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7277789_1\17_1.jpg
PMC7277789,6.56e-05,"Figure 7. Similarity between chemical structures of the luteolin, quercetin, and eriodictyol.Luteolin, quercetin, and eriodictyol have been identiÃ¯Â¬Âed in the recent supercomputer SUMMITdrug-docking screen as top candidate inhibitors of the SARS-CoV-2 spike-proteinÃ¢Â€Â“human ACE2receptor interfaceÃ¢Â€Â“ligand binding complex [42], while Luteolin and quercetin have been identiÃ¯Â¬Âed aspotent inhibitors of the SARS-CoV infection [43].",doi.org/10.3390/biomedici-1es8050129,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7277789_1\20_1.jpg
PMC7277789,6.56e-05,Figure 8. Proposed mitigation approaches for prophylaxis and treatment of the COVID-19pandemic based on prescriptions of bipartite (vitamin D and quercetin) and tripartite (vitaminD/quercetin/estradiol) combinations of candidate therapeutics.,doi.org/10.3390/biomedici-1es8050129,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7277789_1\23_1.jpg
PMC7277789,6.56e-05,"Figure A1. Similarity of chemical structures of the Quercetin, Taxifolin, and Rhemnetin. Taxifolinand rhemnetin have been identiÃ¯Â¬Âed in the recent a chemical library of over 687 million compoundsfor binding at the recently solved crystal structure of the main protease of SARS-CoV-2 coronavirus(Fischer et al., 2020. https://doi.org/10.26434/chemrxiv.11923239.v2 ) among the top-scoring candidateinhibitors of the SARS-CoV-2 main protease.",doi.org/10.3390/biomedici-1es8050129,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7277789_1\24_1.jpg
PMC7277789,6.56e-05,Figure 1. Cont.,doi.org/10.3390/biomedici-1es8050129,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7277789_1\4_1.jpg
PMC7277789,6.56e-05,Figure 1. Genomic-guided mapping of regulatory networks aÃ¯Â¬Â€ecting expression of human genesencoding protein targets of SARS-CoV-2 enables identiÃ¯Â¬Âcation of putative 2019 coronavirus disease(COVID-19) mitigation agents. (A). Flow chart of a decision-making process during the identiÃ¯Â¬Âcationof candidate pandemic mitigation agents employing genomic-guided tracing of genetic regulators andbiological and chemical eÃ¯Â¬Â€ectors of SARS-CoV-2 targets in human cells. (B) and (C). EÃ¯Â¬Â€ects of viralchallenges on expression of the ACE2 and FURIN genes. (B). Gene Set Enrichment Analyses (GSEA) ofthe Virus Perturbations from GEO focused on upregulated genes (Enrichr bioinformatics platform).SARS-CoV p value = 0.0002; q value = 0.072). Star denotes the SARS-CoV record at the 96 hrs. (C).Increased FURIN expression in peripheral blood mononuclear cells (PBMC) of patients with severeacute respiratory syndrome (SARS). p value = 0.002; q value = 0.126.,doi.org/10.3390/biomedici-1es8050129,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7277789_1\5_1.jpg
PMC7277789,6.56e-05,Figure 2. Pathways and genes aÃ¯Â¬Â€ecting the newly emerged SARS-CoV-2 virus-related host targets.(A). JNK1/c-FOS pathway-associated activation of the ACE2 and FURIN expression may trigger the,doi.org/10.3390/biomedici-1es8050129,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7277789_1\7_1.jpg
PMC7277789,6.56e-05,Figure 3. Cont.,doi.org/10.3390/biomedici-1es8050129,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7277789_1\8_1.jpg
PMC7277789,6.56e-05,"Figure 3. EÃ¯Â¬Â€ects of the VDR gene and vitamin D on pathways and genes aÃ¯Â¬Â€ecting the newly emergedSARS-CoV-2 virus-related host targets. (A). JNK1/c-FOS pathway-associated activation of the ACE2 andFURIN expression may trigger the auto-regulatory negative feed-back loop of the FURIN-mediatedrepression of the expression of JUN, JUNB, JUND, and c-FOS genes. (B). HNF4a pathway-associatedactivation of the ACE2 and FURIN expression may trigger the auto-regulatory positive feed-back loopof the FURIN-mediated activation of the HNF4a expression. Activation of VDR gene would blockJNK1/c-FOS- and HNF4a-mediated increased expression of both ACE2 and FURIN genes.",doi.org/10.3390/biomedici-1es8050129,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7277789_1\9_1.jpg
PMC7331543,5.16e-05,"FIG 2. Treatment strategies for COVID-19. A, Drugs that are designed to block entry of SARS-CoV into the",doi.org/10.1016/j.jaci.2020.05.033,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7331543_1\10_1.jpg
PMC7331543,5.16e-05,"FIG 1. A, Structure of RBD of spike protein S1 of SARS-CoV-2 bound to ACE2. Structure of ACE2 bound tothe RBD of the S1 spike protein of SARS-CoV-2.94-96 The chimeric RBD is in orange, and human ACE2 is ingreen. The Ã¯Â¬Âgure was created with Research Collaboratory for Structural Bioinformatics Protein Data Bank(https://www.rcsb.org/). RBD, RBD of S1 spike protein of SARS-CoV-2. B, Cartoon showing how SARS-CoV-2",doi.org/10.1016/j.jaci.2020.05.033,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7331543_1\6_1.jpg
PMC7355517,8.83e-05,Figure 1: Study ALXN1210-COV-305 Schematic,doi.org/10.1186/s13063-020-04548-z,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7355517_1\21_1.jpg
PMC7373263,5.5e-05,"Fig 3. Illustrative simulations of the transmission model. (A, B) Shows the number of diagnoses and the attack rateduring the first 12 months after the first case under three model scenarios. The red lines correspond to the baselinetransmission model. The orange lines correspond to the model with a fast rate of awareness spread and nointerventions. The blue lines correspond to the latter model, where disease awareness induces the uptake ofhandwashing with an efficacy of 30%.",doi.org/10.1371/jour-1l.pmed.1003166,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7373263_6\11_1.jpg
PMC7373263,5.5e-05,"Fig 4. Impact of prevention measures on the epidemic for a slow rate of awareness spread. (AÃ¢Â€Â“C) Shows therelative reduction in the peak number of diagnoses, the attack rate (proportion of the population that recovered or diedafter severe infection), and the time until the peak number of diagnoses. The efficacy of prevention measures wasvaried between 0% and 100%. In the context of this study, the efficacy of social distancing denotes the reduction in thecontact rate. The efficacy of handwashing and mask-wearing are given by the reduction in susceptibility andinfectivity, respectively. The simulations were started with one case. Government-imposed social distancing wasinitiated after 10 diagnoses and lifted after 3 months. For parameter values, see Table 1. Please note that the blue linecorresponding to handwashing is not visible in (C) because it almost completely overlaps with lines for mask-wearingand self-imposed social distancing.",doi.org/10.1371/jour-1l.pmed.1003166,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7373263_6\12_1.jpg
PMC7373263,5.5e-05,"Fig 5. Impact of prevention measures on the epidemic for a fast rate of awareness spread. (AÃ¢Â€Â“C) Shows the relativereduction in the peak number of diagnoses, the attack rate (proportion of the population that recovered or died aftersevere infection), and the time until the peak number of diagnoses. The efficacy of prevention measures was variedbetween 0% and 100%. In the context of this study, the efficacy of social distancing denotes the reduction in the contactrate. The efficacy of handwashing and mask-wearing are given by the reduction in susceptibility and infectivity,respectively. The simulations were started with one case. Government-imposed social distancing was initiated after 10diagnoses and lifted after 3 months. For parameter values, see Table 1. Please note that the blue line corresponding tohandwashing is not visible in (A) because it almost completely overlaps with lines for mask-wearing and self-imposedsocial distancing.",doi.org/10.1371/jour-1l.pmed.1003166,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7373263_6\14_1.jpg
PMC7373263,5.5e-05,"Fig 6. Impact on the epidemic of a combination of government-imposed social distancing and handwashing. (AÃ¢Â€Â“C) Shows the relative reduction in the peak number of diagnoses, the attack rate (proportion of the population thatrecovered or died after severe infection), and the time until the peak number of diagnoses. The efficacy ofhandwashing was 30%, 45%, and 60%. In the context of this study, the efficacy of social distancing denotes thereduction in the contact rate. The efficacy of handwashing is given by the reduction in susceptibility. The simulationswere started with one case. Government-imposed social distancing was initiated after 10 diagnoses and lifted after 3months. For parameter values, see Table 1.",doi.org/10.1371/jour-1l.pmed.1003166,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7373263_6\15_1.jpg
PMC7373263,5.5e-05,"Fig 1. Schematic of the baseline transmission model. Black arrows show epidemiological transitions. Red dashedarrows indicate the compartments contributing to the force of infection. Susceptible persons (S) become latentlyinfected (E) with the force of infection ÃŽÂ»inf via contact with infectious individuals in two infectious classes (IM and IS).Individuals leave the E compartment at rate ÃŽÂ±. A proportion p of the latently infected individuals (E) will go to the IMcompartment, and the proportion (1Ã¢ÂˆÂ’p) of E individuals will go to the IS compartment. Infectious individuals withmild disease (IM) recover without being conscious of having contracted COVID-19 (RM) at rate ÃŽÂ³M. Infectiousindividuals with severe disease (IS) are diagnosed and kept in isolation (ID) at rate ÃŽÂ½ until they recover (RS) at rate ÃŽÂ³S ordie at rate ÃŽÂ·. Table 1 provides the description and values of all parameters.",doi.org/10.1371/jour-1l.pmed.1003166,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7373263_6\5_1.jpg
PMC7373263,5.5e-05,"Fig 2. Schematic of the transmission model with disease awareness. (A) Shows epidemiological transitions in thetransmission model with awareness (black arrows). The orange dashed lines indicate the compartments thatparticipate in the awareness dynamics. The red dashed arrows indicate the compartments contributing to the force ofinfection. Disease-aware susceptible individuals (Sa) become latently infected (Ea) through contact with infectiousindividuals (IM, IS, IMa , and ISa) with the force of infection lainf . Infectious individuals with severe disease who aredisease-aware (ISa) get diagnosed and isolated (IDa ) at rate ÃŽÂ½a, recover at rate gaS, and die from disease at rate ÃŽÂ·a. (B)Shows awareness dynamics. Infectious individuals with severe disease (IS) acquire disease awareness (ISa) at rate ÃŽÂ»awareproportional to the rate of awareness spread and to the current number of diagnosed individuals (ID and IDa ) in thepopulation. As awareness fades, these individuals return to the unaware state at rate ÃŽÂ¼S. The acquisition rate ofawareness (kÃŽÂ»aware) and the rate of awareness fading (ÃŽÂ¼) are the same for individuals of types S, E, IM, and RM, where kis the reduction in susceptibility to the awareness acquisition compared to IS individuals. Table 1 provides thedescription and values of all parameters.",doi.org/10.1371/jour-1l.pmed.1003166,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7373263_6\6_1.jpg
PMC7388426,7.55e-05,Figure 1 Participant flowchart,doi.org/10.1186/s13063-020-04621-7,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7388426_2\7_1.jpg
PMC7391030,5.16e-05,Fig. 4 Web of ScienceÃ¢Â€Â•results analysis tool,doi.org/10.1007/s13167-020-00218-x,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7391030_1\10_1.jpg
PMC7391030,5.16e-05,Fig. 5 Collaboration network as asocial structure of COVID-19scientific research records in 2020,doi.org/10.1007/s13167-020-00218-x,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7391030_1\10_2.jpg
PMC7391030,5.16e-05,Fig. 5 Collaboration network as asocial structure of COVID-19scientific research records in 2020,doi.org/10.1007/s13167-020-00218-x,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7391030_1\10_3.jpg
PMC7391030,5.16e-05,Fig. 6 Historic analysis of scientific research on global pandemics 1900Ã¢Â€Â“2020,doi.org/10.1007/s13167-020-00218-x,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7391030_1\11_1.jpg
PMC7391030,5.16e-05,Fig. 7 Digital solutions for pandemic management,doi.org/10.1007/s13167-020-00218-x,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7391030_1\13_1.jpg
PMC7391030,5.16e-05,Fig. 8 Blockchain in digital health systems integrated to COVID-19 virtual clinics,doi.org/10.1007/s13167-020-00218-x,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7391030_1\18_1.jpg
PMC7391030,5.16e-05,Fig. 1 Pandemic as an epidemic on a national or global level,doi.org/10.1007/s13167-020-00218-x,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7391030_1\6_1.jpg
PMC7391030,5.16e-05,Fig. 2 Results of a statistical bibliometric analysis of the 500 most relevant research records on COVID-19,doi.org/10.1007/s13167-020-00218-x,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7391030_1\9_1.jpg
PMC7391030,5.16e-05,Fig. 3 Corresponding author by countryÃ¢Â€Â•COVID-19 research in 2020,doi.org/10.1007/s13167-020-00218-x,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7391030_1\9_2.jpg
PMC7391030,5.16e-05,Fig. 3 Corresponding author by countryÃ¢Â€Â•COVID-19 research in 2020,doi.org/10.1007/s13167-020-00218-x,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7391030_1\9_3.jpg
PMC7393246,0.00011178200000000001,Figure 1. Number of confirmed cases in Emilia Romagna Region (report 23 March 2020),doi.org/10.1186/s13063-020-04527-4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7393246_1\16_1.jpg
PMC7393246,0.00011178200000000001,Figure 2. Number of cases in Emilia Romagna Region (report 24 March 2020),doi.org/10.1186/s13063-020-04527-4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7393246_1\20_1.jpg
PMC7393246,0.00011178200000000001,Figure 3 Binding of viral spike protein to receptor ACE-2 [19],doi.org/10.1186/s13063-020-04527-4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7393246_1\22_1.jpg
PMC7393246,0.00011178200000000001,Figure 4 Classification of COVID-19 disease states and potential therapeutic target [21]IRST100.47 PROTECTFinal Version_15.04.20,doi.org/10.1186/s13063-020-04527-4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7393246_1\23_1.jpg
PMC7393246,0.00011178200000000001,"Figure 5. Percentage of patients with PCR-positive nasopharyngeal samples from inclusion to day6 post-inclusion in COVID-19 patients treated with hydroxychloroquine only, in COVID-19 patients treated withhydroxychloroquine and azithromycin combination, and in COVID-19 control patients [23]",doi.org/10.1186/s13063-020-04527-4,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7393246_1\25_1.jpg
PMC7538834,5.3e-05,FIGURE 4 | Survey group moderating the relationship between COVID-19 stress and crisis of meaning.,doi.org/10.3389/fpsyt.2020.582352,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7538834_1\10_1.jpg
PMC7538834,5.3e-05,FIGURE 5 | Self-control moderating the relationship between crisis of meaning and general mental distress.,doi.org/10.3389/fpsyt.2020.582352,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7538834_1\10_2.jpg
PMC7538834,5.3e-05,"FIGURE 1 | Meaningfulness and self-control moderate the relationship between COVID-19 stress and general mental distress (double moderation, PROCESS model 2).",doi.org/10.3389/fpsyt.2020.582352,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7538834_1\4_1.jpg
PMC7538834,5.3e-05,"FIGURE 2 | Crisis of meaning mediates the relationship between COVID-19 stress and general mental distress, with self-control and group as moderators (dualmoderated mediation, PROCESS model 21).",doi.org/10.3389/fpsyt.2020.582352,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7538834_1\5_1.jpg
PMC7538834,5.3e-05,FIGURE 3 | Meaningfulness and self-control moderating the relationship between COVID-19 stress and general mental distress.,doi.org/10.3389/fpsyt.2020.582352,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7538834_1\9_1.jpg
PMC7565143,7.44e-05,Figure 2. Suggested scenarios for the coronavirus disease 2019 (COVID-19) pathogenicity in old andyoung patients.,doi.org/10.3390/biom10091312,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7565143_1\13_1.jpg
PMC7565143,7.44e-05,Figure 1. Suggested scenarios for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)cellular entry pathways and their potential eÃ¯Â¬Â€ects on the viral load and transmission capability.,doi.org/10.3390/biom10091312,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7565143_1\8_1.jpg
PMC7594416,0.000360707,"Figure 1. Weak-base drug distribution with lysosomal sequestration, uncharged molecules can freely diffuse acrossthe lysosomal and plasma membranes while protonated (charged) molecules are trapped inside the acidicenvironment of lysosomes10",doi.org/10.1186/s13063-020-04819-9,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7594416_2\12_1.jpg
PMC7594416,0.000360707,"Figure 2. Antiviral activity of imatinib mesylate. Vero E6 cells were infected with MERS-CoV or SARS-CoV at anMOI of 0.1 or 1, respectively, and treated for 48 h with eight doses of imatinib mesylate (B). Antiviral activity isshown in blue, and cytotoxicity is shown in red. EC50s are indicated. Results are representative of one experiment(means SEM; n = 2).13",doi.org/10.1186/s13063-020-04819-9,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7594416_2\13_1.jpg
PMC7594416,0.000360707,"Figure 3. Imatinib attenuates vascular leak in mice challenged with a 2-hit model of LPS and mechanical ventilation(MV). Mice were challenged with LPS [0.5 mg/kg, intratracheally (it)] (t = 0 h) and MV (respiratory rate 75, tidalvolume 30 ml/kg, positive end-expiratory pressure 0 cm H2O) (t = 20Ã¢Â€Â“24 h) as outlined in A. Spontaneously breathing(SB) control mice received PBS (vs. LPS) and were intubated for 4 h without MV. Bronchoalveolar lavage (BAL)fluid, plasma, and lungs were harvested from the animals immediately after MV. Imatinib (IM) (75 mg/kg, ip) orvehicle was administered 0.5 h before LPS administration and before the initiation of MV. Lung permeability wasassessed by BAL protein content (B), BAL fluid albumin (C), and lung tissue albumin (D). Additionally, in separateanimals, Evans Blue dye (EBD) was injected (30 mg/kg, iv) 1 h before harvest, and representative extravasation intoharvested lung tissue is shown (E) and quantified in multiple samples (F). The left lung of each of these animals wasused for calculation of lung wet:dry ratio (G). SB (n = 3), SB + imatinib (n = 3), LPS + ventilator-induced lung injury(VILI) (n = 3Ã¢Â€Â“11) and LPS + VILI + imatinib (n = 3Ã¢Â€Â“6). *P < 0.05 compared with SB controls and #P < 0.05compared with untreated animals.20",doi.org/10.1186/s13063-020-04819-9,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7594416_2\14_1.jpg
PMC7594416,0.000360707,"Figure 4. Imatinib decreases lung inflammation in mice challenged with LPS and MV. Mice were subjected to the 2-hit lung injury model (LPS + VILI), and lung inflammation was quantified by BAL total cell counts (A) and BALneutrophil counts (B). Representative hematoxylin and eosin (H and E)-stained lung sections are shown (C). Each Hand E image was obtained from a different animal. SB (n = 3), SB + imatinib (n = 3), LPS + VILI (n = 3Ã¢Â€Â“11), andLPS + VILI + imatinib (n = 3Ã¢Â€Â“6). *P < 0.05 compared with SB controls and #P < 0.05 compared with untreatedanimals.20",doi.org/10.1186/s13063-020-04819-9,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7594416_2\15_1.jpg
PMC7594416,0.000360707,"Figure 5. Imatinib decreases LPS-induced vascular leak when given after injury onset. Mice were challenged withLPS (1.0 mg/kg, it) (vs. PBS) and then received imatinib (75 mg/kg, ip) (vs. vehicle) 4 h later. Samples wereharvested 18 h after LPS administration. Pulmonary vascular permeability was quantified in these animals bymeasuring BAL protein (A), BAL albumin (B), and lung tissue albumin (C). In separate animals, EBD was injected(30 mg/kg, iv) 1 h before harvest, and representative extravasation into harvested lung tissue is shown (D) andquantified in multiple samples (E). The left lung of each of these animals was used for calculation of lung wet:dryratio (F). SB (n = 3), SB + imatinib (n = 3), LPS (n = 3Ã¢Â€Â“6), and LPS + imatinib (n = 3Ã¢Â€Â“6). *P < 0.05 compared withSB controls and #P < 0.05 compared with untreated animals.20",doi.org/10.1186/s13063-020-04819-9,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7594416_2\16_1.jpg
PMC7594416,0.000360707,"Figure 6. Imatinib inhibits LPS-induced NF-ÃŽÂºB phosphorylation and nuclear translocation in vitro. Humanpulmonary artery endothelial cells (HPAEC) were treated with imatinib (40 ÃŽÂ¼M, 60 min) and then challenged withLPS (1 ÃŽÂ¼g/ml, 0Ã¢Â€Â“60 min). Lysates were harvested for Western blots for phosphorylated NF-ÃŽÂºB p65 (S536), total NF-ÃŽÂºB p65 protein, IÃŽÂºB, and actin and quantified by densitometry (A and B). HPAEC plated on glass coverslips weresubjected to identical conditions, and immunofluorescence microscopy was conducted to determine the localizationof total NF-ÃŽÂºB p65 protein (red). 4Ã¢Â€Â²,6-diamidino-2-phenylindole (DAPI) (blue) was used to stain the nuclei (whitearrows) (C). Data are representative of 3 independent experiments. *P < 0.05 compared with nonchallengedsamples.20",doi.org/10.1186/s13063-020-04819-9,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7594416_2\17_1.jpg
PMC7594416,0.000360707,"Figure 7. Imatinib decreases NF-ÃŽÂºB expression in mouse lungs after LPS. Mice were challenged with LPS (1.0mg/kg, it) (vs. PBS) and then received imatinib (75 mg/kg, ip) (vs. vehicle) 4 h later. Lung tissue homogenates werecollected, subjected to Western blotting for total NF-ÃŽÂºB p65 protein, and quantified by densitometry (A and B). Lanesin A represent lung homogenates from individual animals. Representative immunohistochemistry images are shownfor NF-ÃŽÂºB p65 taken by an individual blinded to experimental condition (C). *P < 0.05.20",doi.org/10.1186/s13063-020-04819-9,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7594416_2\18_1.jpg
PMC7642977,0.000132236,"Fig. 1. Age range among patients presenting to the screening clinic of Rehman Medical Institute, Peshawar.",doi.org/10.1099/jmm.0.001231,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7642977_1\4_1.jpg
PMC7717016,6.1e-05,"Figure 1. Recall of alleged symptoms for SARS-CoV-2 infection among study participants, broken down by being or not a health-care worker (HCW). Univariate comparisons were performed by means of chi squared test (only p value < 0.05 are reported)",doi.org/10.23750/abm.v91i3.9727,C:\Users\sean0\Desktop\Programming Stuff\FYP\Implementation\pmc_figures_captions\PMC7717016_1\4_1.jpg
